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ABSTRACT
The purpose of this research project was to evaluate
the role of the community pharmacist in screening,
identifying, and referring ambulatory patients with high
total blood cholesterol (TBC) in a community pharmacy.
Fifty seven patients, out of 241 initially screened
individuals, met the study inclusion criteria and were
accepted into this study.

Of these 57 patients, 51

patients completed the six month study period.

The normal

population group consisted of 164 participants with TBC <
200 mgjdL at the initial cholesterol testing (visit 1).
The drop out group represented six patients who failed to
continue attending the two follow up tests (visit 2 and 3).
For screening purposes, a non-fasting whole blood sample
was used to measure TBC using the Boehringer Mannheim
Reflotron analyzer.
The project was evaluated based on mean TBC levels
obtained during the initial screening and the two follow up
tests, pre-test and post-test scores, behavior and
lifestyle changes, and the number of patients who received
a physician's order for lipid analysis as a result of
initial screening results.

In addition, influence of age

and educational background on lowering TBC in visits 2 and
3, patient acceptance of blood screening in a community
pharmacy and willingness to pay for this service in the
future were also determined.

i

To assess the level of significance among the means
of the tested parameters, both parametric (one-way analysis
of variance, Scheffe's post hoc test and two sample t-test)
and non-parametric statistics (Mann-Whitney and chi-square
test) were used at a probability level of less than 0.05.
There was a significant difference in mean TBC levels
between visit 1 and 2, and between visit 1 and 3 (P< 0.01).
However, no statistically significant difference was found
between visit 2 and 3 (P= 0.48).

In addition, there was no

significant difference in the incidence of high blood
cholesterol in terms of gender or age difference at the
initial screening.

Further, mean TBC levels between males

and females remained statistically insignificant during the
two follow up tests.

However, younger patients were able

to lower their mean TBC level in visit 2 and 3 compared
with older patients (P=< 0.031).

The one-way analysis of

variance results showed that there was no statistically
significant difference in TBC changes during the three
visits by subjects categorized by educational background
levels.

Patient's attitude toward the idea of blood test

measurement in community pharmacies was positive.

Ninety

eight percent of the study group stated that they strongly
liked such an idea, 92.16% expressed a willingness to pay
an average of $4.55 (range $3 or less to $10), and all
agreed that it was a convenient service for them.
It was concluded that cholesterol screening in this
ii

community pharmacy was effective and acceptable, and may
prove to be financially feasible when effectively planned
and marketed.

This service provides the community

pharmacist with an opportunity to offer a unique patientoriented public service.

iii
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INTRODUCTION
Historical Background
cardiovascular disease (CVD) is the major cause of
death and disability in the United states.
more deaths than all forms of cancer

•

It accounts for

comb~ned.

1-3

Coronary

heart disease (CHD) strikes about five million Americans
and is the cause of 550,000 deaths in the United states
yearly. 3 •4

The direct and indirect cost of CVD and CHD has

been estimated at $85.21 and $64.4 billion a year,
respectively. 2 ' 6

It was postulated that lowering blood

cholesterol would result in direct benefits from
anticipated reductions in lifetime expenditures for medical
care.

Indirect benefits result from an expected extension

of work-life secondary to reduction in morbidity and
mortality. 5
According to the updated statement of the .1970 InterSociety Commission for Heart Disease Resources, there has
been a significant decline in CVD mortality (35-40%) that
appears to be continuing to the present.

This decline in

CVD as well as the distinct reduction in CHD mortality has
coincided with a more effective control of hypertension,
cigarette smoking, and lower consumption of fat and
cholesterol in the American diet. 5

It has been es.timated

that 60% of such decline in CHD mortality was attributed to
life style changes and 40% due to medical intervention. 7
This association was attributed to environmental
1

2

influences, since genetic characteristics of a population
cannot change in a short time.

Pathologic and experimental

observations support such association both in animal and
human studies.
Broad scientific studies ascertained the association
between elevated serum lipids, due to either hereditary
andjor life style, and the development of atherosclerosis
and associated CHD.

Further, the linear relationship

between plasma lipid concentration, especially cholesterol,
and the severity of atherosclerosis is well
established. 5 •8 - 13

The early atherosclerotic lesions can

cause significant narrowing of the blood vessels.

However,

this is a slowly developing process and presents no
clinical symptoms in most cases.

It is not until a

significant occlusion of the vessel, due to calcification
and fibrosis, that a clinically active period can be
observed.

This lesion is usually common in the fifth or

sixth decade of life. 14

Variation in patient

susceptibility is wide and is dependent on the type and
intensity of underlying risk factors and the duration of
exposure to those risk factors.

It is important to keep in

mind that the clinical manifestations of coronary heart
disease often strike without warning.

It is quite possible

that the first manifestation is an irreversible brain or
myocardial infarction or even sudden death.

Therefore,

emphasis on primary prevention is of a great importance.

----- ---

3

Hyperlipidemia
Hyperlipidemia (HLP) is defined as an elevation of
plasma lipids, namely, cholesterol, triglycerides, and
phospholipids.

Hyperlipoproteinemia is a disturbance of

lipid transport that results from abnormalities in the
.
.
synth es~s
or d egra d at~on
o f p 1 asma 1.~popro t

.
10 15·19
e~ns.

•

Diverse proportions of cholesterol ester and triglycerides
act as a core for high molecular weight particles called
lipoproteins.

In order for these particles to travel in

the circulatory system, a surface coat of phospholipids,
which is polar in nature, is needed.

In addition to

phospholipids, the polar coat contains small amounts of unesterified cholesterol.

These components represent

lipoprotein (LP) particles.

The outer surface of LP

particles contains specific proteins, called apoproteins,
which have the ability to bind to specific enzymes or
transport proteins on cell membranes.

Therefore, these

apoproteins are of great importance in directing the
lipoprotein particles to their sites of metabolism. 10 • 15
There are five different classes of LP that normally
circulate in human blood.

They differ in their density,

particle size, electrophoretic mobility, core composition,
and the apoproteins in their surfaces. 18 • 20

The five main

types are chylomicron, very low density lipoprotein (VLDL),
intermediate low density lipoprotein (IDL), low density
lipoprotein (LDL), and high density lipoprotein (HDL).

The

biochemical and clinical features of these lipoproteins are

4

presented in Table I. 21

5

Table I:
Biochemical and Clinical Features of Lipoproteins. 1
----------~------------------------------~
Lipoprotein
Chylomicron

~---------~------------------------------Composition (%)
3-7
85-95
1-2
3-6

20-30
50-65
6-10
15-20

origin

Intestine

Intestine
and liver

Physiological
function

Transports
dietary

Cholesterol
Triglyceride
Protein
Phospholipid
Physiological

triglyceride

Transports
endogenous
triglyceride

51-58

18-25

4-B

2-7

18-22
18-24

45-55
26-32

VLDL

Liver and
intestine

catabolism
Transports
cholesterol
to extra-

hepatic cells

Electrophoretic
mobility

Appearance in
plasma after
refrigeration

l
j

l

"

Origin

Transports
cholesterol
from extrahepatic celt
to liver

Pre-beta

Beta

Alpha

Turbid

Clear

Clear

Glucose
intolerance;
hyperurice-:nia

Premature
atheroscleros1s; corneal
arcus; tendious and
tuberous
xanthoma

No

cream layer
at surface

Clinical features Eruptive
of high level
xanthomas;
lipemia
retinal is;
pancreatitis;
organomegaly

1Adapted from Reference #18 and #21.
2very low density lipoprotein.
3Low density lipoprotein.
4High density lipoprotein.

associated
abnormality

6

In order to understand the etiologies of the lipid
disorders, CHD, and approaches to their treatment, a brief
review of lipid transport and metabolism is presented.
Lipid Transport
Two pathways are involved in the transportation of
lipids in our circulatory system, namely, the exogenous and
the endogenous pathways.
a.

Exogenous Pathway
The exogenous pathway involves the largest amount of

lipoprotein which transports more than 100 grams of
triglycerides and about one gram of cholesterol per day.
Exogenous fat and cholesterol are incorporated within
intestinal epithelial cells into a large LP called
chylomicron.

These particles reach the general

circulation through intestinal lymph channels where they
are subsequently transported to the capillaries of adipose
tissues and skeletal muscle. 15

Chylomicrons are then

exposed to the enzyme lipoprotein lipase (LPL) which is
activated by apoprotein CII located on their surfaces.

As

a result, free fatty acids and monoglycerides are liberated in capillaries, where they reach adipocyte or muscle
cells for subsequent oxidation or re-esterification to
triglycerides.
The remainder of the chylomicron dissociates from the
capillary endothelium and reenters the circulation as a
remnant particle (IDL) . These particles travel to the
liver, where they are effectively taken up through binding

7

of apolipoprotein E to its specific receptors on the
surface of the hepatocyte.

The surface-bound remnants are

then taken into the cell and then degraded within lysosomes
. t e d en d ocy t os1s.
. 15 ' 22 •23
by the process called receptor-me d 1a
In summary, the overall result of the chylomicron transport
process is to deliver dietary triglycerides to adipose
tissues and cholesterol to the liver.
b.

Endogenous Pathway
Between meals, free fatty acids are usually released

from adipose tissue and supplied to the liver where about
80% are used for energy.

The rest of the free fatty acids

are incorporated into VLDL particles along with
cholesterol, phospholipids, and apolipoprotein.

The VLDL

particles are then secreted into the circulation.
Therefore, whereas chylomicron particles carry
triglycerides of dietary origin, VLDL particles carry
triglycerides of endogenous origin.

These later

triglycerides have been formed from excess fat stored in
and

mobilized from adipose tissue.

The VLDL particles are

then exposed to the same LPL enzyme where triglycerides are
removed from its core leading to smaller and denser IDL
particles.

These newly formed particles are metabolized

and removed from the circulation by two different
mechanisms.

First, they may be taken up by specific

receptors on the surface of the liver. Second, 50% may be
converted to LDL particles via hepatic triglyceride lipase
enzyme.

The result of these two mechanisms is a release of

8

LDL particles with a very rich amount of cholesterol into
the general circulation.

These LDL particles transport

cholesterol to peripheral cells that utilize cholesterol
for cell membrane and hormonal synthesis.
Since LDL particles contain 60-70% cholesterol,
inefficient removal of LDL from the circulation can result
in high blood cholesterol levels.

Therefore, the longer

the circulation time of LDL particles, the more likely they
are taken up by scavenger cells (macrophage) .

The

scavenger cells are then converted to cholesterol-laden
foam cells.

It has been postulated that these macrophage

cells are involved in the initial formation of the
atherosclerotic lesion. 11 • 24
In the presence of lecithin cholesterol
acetyltransferase (LCAT), cholesterol from LDL particles is
esterified to form HDL particles.

These particles deliver

the cholesterol ester to the liver where it is removed and
degraded by bile acids.

l
•

Bile acids are then secreted into

the intestine to facilitate fat metabolism.

Thus, it is

claimed that people with high LDL levels are more likely to
develop atherosclerotic lesions and subsequent CHD.

On the

other hand, people with high levels of HDL tend to have an
enhanced ability to remove cholesterol from foam cells and,
therefore, are at low risk of developing
atherosclerosis. 11 • 25 " 27
Phenotype Classification of Hyperlipidemia
The hyperlipidemias were initially classified based on

9

their electrophoretic lipoprotein pattern first suggested
by Fredrickson and Lee. 16 • 28

This classification has proved

to be useful in classifying familial (primary) disorders or
genetic abnormalities.

However, it provides little

information about the etiology of the lipid disorders and
no information about altered concentrations of apoproteins
or HDL or alteration in enzymatic activity.

The American

Heart Association in 1984 suggested a classification based
on an etiology that would be more practical when evaluating
the patient. This new classification system consists of
three general categories that focus on the cause of
hyperlipidemia.

It entails secondary causes such as

disorders in related metabolic systems, the use of certain
medications, and abnormal dietary intake and lifestyle. 15 17,29

Brown and Goldstein 15 subdivided primary HLP into two
major categories.

The first category includes single-gene

disorders which are transmitted by a simple recessive
mechanism, while the second category includes a
multifactorial disorder with complex inheritance patterns.
It was stated that hyperlipidemias of type II, III, and IV
are associated primarily with premature coronary artery
disease, whereas profound hypertriglyceridemia of type I
and V is often complicated by pancreatitis. 14

A summary of

the major hyperlipoproteinemias and their phenotype-disease
classification is presented in Table II. 10
In contrast to the primary causes of

HLP, the

10

Table II:
Major Hyperlipidemias, Their Phenotype-Disease
Classification, and Clinical Manifestations. 1

...------------------------,-----Occu-

Phenotype

rence

Elevated
Lipoprotein

Plasma Lipid
Concentration

Clinical

Manifestation

(mg/dL)
Chot 2

TG3

250·
400

>2500

Hepatosplenomegaly;
pancreatitis;
eruptive xanthomas;
onset in childhood.

>250

<150

Premature CHD5;
tendon xanthoma;
detectable in
childhood.
Premature CHD;
milder form associated with obesity or
diabetes.
Premature CHD and
peripheral vascular
disease; hyperglycemia; hyperuricemia
in adult.
Premature CHD risk;
eruptive xanthomas;
hyperuricemia.

!-----------------·--,----Rare

Chylomicron

!!A

Common

IIB

Most
Common

LDL, VLDL6

>250

150·
400

!! I

Rare

VLDL
remnant

375500

600·
800

IV

Common

VLDl

225275

375·
500

v

Rare

Chylomicron,

350400

17002500

VLDL

lAdapted from Reference #B and #18.
2cholesterol.
3Triglyceride.
4coronary heart disease.
5very low density lipoprotein.

Hepatosplenomegaly;
pancreatitis; eruptive
xanthomas. lipemia
retinalis; mainly in
adults.

11

secondary causes, including disease state, drug therapy, or
lifestyle, are usually reversible if they were
appropriately identified.

In some cases, however,

multifactorial inherited disorders might interact with
environmental factors to produce a more serious form of
lipid disorder. 8 •15

12
Blood Cholesterol
Cholesterol belongs to the class of compounds that is
characterized by the basic steroidal carbon skeleton.

It

is a fat-like steroid alcohol with a structural formula
C27H45 oH.

Cholesterol is found in animal fats and oils, in

bile, blood, brain tissue, milk, egg yolk, myelin sheaths
of nerve fiber, the liver, kidney, and adrenal glands.

It

is a precursor of bile acids and is an important component
in the synthesis of steroidal hormones.•
In spite of the fact that liver is the major site and
source of cholesterol biosynthesis, nearly all body cells
have the ability to synthesize cholesterol.

Blood

cholesterol circulates mainly in the form of LDL (65%),
VLDL (15%), and HDL (20%).

Hagan, et al., reported that

movement from a 30 minute supine position to the standing
position caused a 9.3 % increase in total cholesterol due
to hemoconcentration.

However, he stated that the TC/HDL

ratio was not affected by such posture changes. 30
The blood cholesterol level is a sum of both exogenous
cholesterol and saturated fats from foods we eat and
cholesterol that is endogenously generated by the liver.
It is under restricted biochemical and enzymatic regulation
including a sensitive feed back mechanism.

This mechanism

responds to both the blood cholesterol level and

• Dorland's Illustrated Medical Dictionary. Friel J.P.
(Ed.). Twenty-Sixth Edition. W.B. Saunders Company.
Philadelphia. 1981; p.261.

f

I

l
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lipoprotein receptor number, sensitivity and
integrity. 10 • 15 •22 •31

Most circulating blood cholesterol is

removed by converting it to bile acids in the liver.

These

bile acids are returned to the liver through the
enterohepatic circulation.. The unabsorbed fraction is
degraded in the large intestine and subsequently excreted
in the feces.

Blood cholesterol level is affected by the

rate of lipoprotein synthesis and degradation.

This

process is affected by the presence of efficient or
defective lipoprotein receptors both in hepatic and
extrahepatic tissues.

Therefore, a genetic defect in LDL

receptors could result in a dramatic reduction of the LDL
metabolic pathway (uptake) leading to hypercholesterolemia. 5 • 10 • 22

In such a person, a build up of

circulating LDL particles may occur in spite of eating a
normal or low fat, low cholesterol diet.

Presence of a

high level of LDL and cholesterol in the blood, especially
in the presence of local intimal lesions or hypertension,
can lead to deposition of these particles in large and
medium arteries.

In addition, high blood cholesterol may

suppress the synthesis of the hepatic LDL receptors. A slow
but rather progressive build up of LDL with subsequent
smooth muscle proliferation is .the key to the formation of
atherosclerotic plaque. 2 • 11,24,32
An extensive body of scientific knowledge, including
epidemiologic studies and animal studies, established
beyond any reasonable doubt the causal relation between

14
elevated blood cholesterol and CHD. 2 • 5 • 10 • 12 •20 • 32 "34

Yusuf, et

a1., 35 summarized the results of randomized clinical trials
related to lowering blood cholesterol.

He stated that "

at least 22 randomized trials have evaluated reduction of
cholesterol levels on a total of about 40,000 individuals."
Some of these trials used drugs to lower cholesterol; in
three other trials, dietary polyunsaturated fat was
substituted for a saturated fat diet without changing the
total fat intake.

Nine studies were primary trials (where

there was no evidence of CHD at the time of conducting the
study) while the others were secondary trials.

The author

stated that the reduction in CHD was directly related to
both the degree of lowering cholesterol levels and the
duration of such reduction. 35

In the Framingham study, it

has been estimated that a 10% reduction in blood
cholesterol level is associated with a 10% reduction in CHD
with treatment of less than four years duration.

This

effect on CHD is doubled (20% reduction) with more
prolonged treatment.

The risk of CHD begins to increase

steeply in a curvilinear fashion above a cholesterol level
of 200 mgjdL.

It was estimated that this risk is fourfold

in the top 10% as compared with the bottom 10% (Figure
1). 12 • 20 • 23 •32

In addition, Stamler, et al., documented that

this relationship is not a threshold one and is not
restricted to the highest quintiles, i.e., total blood
cholesterol of 221-244 and 245 mgjdL or more, "but rather
is a continuously graded one that powerfully affects
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Relationship of Serum Cholesterol to Coronary Heart
Disease Death Rate in 361, 662 Men, Age 35 - 57
During the Average Followup of Six Years
(Reference #20).
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risk for the great majority of middle-aged American men." 9
It was concluded, that reducing high cholesterol levels,
particularly early in adult life and on a long term basis,
can lead to a significant reduction in CHD. 35
a.

Effect of Dietary Cholesterol
In a typical American diet, the average amount of

cholesterol consumed is 450 mg daily.

The human body

synthesizes sufficient amounts of cholesterol to meet its
daily needs.

The relative importance of dietary saturated

and polyunsaturated fatty acids and cholesterol in
determining the blood cholesterol level has been a
controversial issue. 36

Zanni, et al., reported a

considerable inter-individual heterogeneity in response to
diet. 37

However, as a general rule, ingestion of a diet

high in saturated fats and cholesterol results in an
elevation of serum cholesterol and increases the risk of
CHD. 38

This increase in serum cholesterol was reported to

be linear over the entire range of the amount of
cholesterol ingested.

A concomitant alteration in the

amount of LDL and HDL particles and the cholesterol content
per particle has been documented. 26 •37

It has been estimated

that for each 100 mg cholesterol in 1000 Kcal of diet there
is approximately 12 mgjdL increase in serum cholesterol. 36
In an epidemiologic study, a low cholesterol level has
been claimed to be associated with a higher incidence of
cancer.

However, it was explained that this is likely to

17
be due to

11

hypocholesterolemic effect of some cancer

rather than the carcinogenic effect of lowering
cholesterol level. " 35

In a recent primary prevention

study, it was confirmed that lowering elevated cholesterol
has no influence on the cancer rate. 39 • 40

Another concern

was the occurrence of suicidal deaths in patients with low
TBC.

;--

These concerns about cancer and suicidal deaths

was based on studies of alcoholics and prisoners. 41
McKenney addressed this issue and commented "No causal
relationship has been demonstrated between lowering
cholesterol and cancer, nor were there reports of increased
cancer deaths in the two recent cholesterol lowering
trials", i.e., LRC-CPPT and the Helsinki Heart study.

The

author added "Until lowering cholesterol has been shown to
r

cause cancer, there is no justification for withholding
cholesterol therapy on this basis. 1140

With advanced

knowledge of the complex nature of lipid metabolism, and
application of the latest techniques of cell biology and
advanced research on lipoprotein receptors, it is now clear
that dietary intake of saturated fat and cholesterol does
in fact affect serum cholesterol levels and lipoprotein
composition. 22 • 26 • 36 - 38

A cholesterol/saturated fat index

(CSI) has been calculated based on a modification of the
regression equation computed from metabolic studies.

This

score enables one to determine the relative
hypercholesterolemic/atherogenic potential of a given food
taking into account the food's content of saturated fat and
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cholesterol.

It has been reported that the CSI per 1000

Kcal correlates well with mortality from ischemic heart
disease (r=0.78) in men 55-64 years old from 40
countries. 42
b.

Seasonal Variation in Cholesterol Level
several studies have conveyed the impression that

cholesterol levels exhibit significant seasonal variation
while others were unable to demonstrate significant
variation. 4 • 44 - 47

. Since

serial and periodic cholesterol

determination over several years has not been studied,
these speculations need further investigation.

In

addition, some of the previous studies had limited
statistical analysis of the results, and some based
conclusions on results which were not statistically
significant- 44
The Lipid Research Clinics (LRC) Coronary Primary
Prevention Trial (CPPT) is one well designed study that
described such cyclic seasonal variation in cholesterol
levels.

A cohort of 1446 hypercholesterolemic 35 to 59-

year-old men, initially free of CHD symptoms, were studied.
This study used a uniform method for measuring blood
cholesterol in the 12 LRC centers.

All participants were

maintained on a standard diet and were examined bimonthly
for 7-10 years for cholesterol levels, body weight, and
semiannual dietary assessment. 1 • 44

A highly significant

seasonal effect in serum cholesterol level was found, with
an average decrease of 7.4 mgjdL December 30 compared to
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that of June 30. 1• 44 "47

Such a trend in cholesterol

variation was observed among the 12 LRC centers that
include completely different climates.

Gordon, et al . , 45

pointed out that the magnitude of this seasonal variation
was independent of baseline cholesterol levels as well as
weight and saturated fat and cholesterol intake.

Another

study examined the effect of season on fasting plasma
cholesterol in a group of 80 people seen during spring to
autumn and another group of 73 subjects seen in summer and
winter.

In this study, no seasonal change in cholesterol

levels was observed. 48

several factors were suggested as a

possible cause of such seasonal variation.

These may

include diet, temperature, exercise, duration of daylight,
and intrinsic and biological rhythm.

However, the etiology

and mechanisms for such seasonal patterns or the role of
suggested causal factors remain to be answered. 45 • 47
This seasonal fluctuation in serum cholesterol is
probably of minor importance in terms of the clinical
management of hyperlipidemia.
reported to vary

Serum cholesterol was

about 15 mgjdL from one visit to another

and between different laboratories due to lack of
standardization method between laboratories.

Furthermore,

a wide variety of parameters beside season of the year may
affect serum cholesterol.

Diet, temperature, and physical

activity all are affected, in different ways, by season for
different individuals.

It is important, however, to take

into account such trends in serum cholesterol and to be
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aware of its possible existence when interpreting patient
values.
Secondary Hyperlipidemia
A number of risk factors have been reported to be
strongly associated with a high incidence of
CHD. 2 • 5 • 10, 11 •32 • 49

Among these factors elevated blood

cholesterol, high blood pressure, and cigarette smoking are
the most clearly established. 5 • 7 • 50 "52

In fact, elevated

serum cholesterol is a powerful independent risk factor for
CHD. 49 • 53

With the exception of familial HLP, the three well

established risk factors are considered to be modifiable
factors, i.e., under the patient's control.

These are the

areas suggested as the target in preventive medical care.
Menotti, et al., 50 reported that these three risk factors
apparently"· .. are of universal value within almost any
population group or sample"

based upon the 1984 report of

Inter-society Commission.
Secondary hyperlipidemia may not only be due to
ingestion of high amounts of saturated fat and cholesterol
but also could be due to a pre-existing disease state
andjor as a side effect of the use of
drugs. 5 • 10 • 15 • 20 • 21 • 25 •34 • 49

The most frequently reported forms of

secondary hyperlipidemia were found to occur in association
with cigarette smoking, diabetes mellitus, alcohol
consumption, and ingestion of oral contraceptives.
Additional disease states that might affect serum
lipoprotein include Cushing's syndrome, hypothyroidism,

I=
''[

I

[
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anorexia nervosa, uremia, nephrotic syndrome, primary
biliary cirrhosis, acute hepatitis, lupus erythematosus,
and monoclonal gammopathesis.

Acute emotional stress, as

in extensive burns, myocardial infarction, or gram negative
sepsis, can also cause lipoprotein abnormalities. 10 • 15
a.

Cigarette Smoking
Cigarette smoking in the United States is reported to

be responsible for about 30% of all deaths from CHD
particularly in younger smokers.

It has been reported that

cigarette smokers have a 70% higher mortality from CHD
compared to nonsmokers.

This results in an estimated $19

billion earning loss yearly. 5 • 10 • 51

Cigarette smoking is one

of the major, graded, and independent factors for CHD.

The

risk is even higher in smokers who also have high blood
pressure, elevated blood cholesterol, and in women who are
using oral contraceptives. 5 • 51 •54
Among the CHD risk factors, cigarette smoking is the
most reported preventable cause of CHD deaths in both men
and women. 10 • 51

The risk is proportional to the number of

cigarettes smoked per day, not the number of years a person
had been smoking. 4 •5•10 • 21

Smoking is also associated with

substantial lowering of HDL level, although smokers who
quit smoking for more than one year seem to have HDL levels
equivalent to or slightly higher than those who had never
smoked. 4 • 10 • 21
Smokers were reported to be at a significantly higher
risk of stroke, even after taking age and hypertension into
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consideration.

As with CHD, the risk of stroke increases

as the number of cigarettes smoked increases. 55 •56

Cessation

of cigarette smoking for two years reduces the risk of
stroke, which was found to return back to the same level of
nonsmokers five years after quitting smoking. 55
Deanfield, et al., 54 examined the effect of smoking a
single cigarette followed by exercise on regional
myocardial perfusion in l3 chronic smokers with typical
angina pectoris.

Cigarette smoking was reported to be

associated with a profound silent disturbance of regional
myocardial perfusion and impaired coronary blood supply in
response to exercise compared with the

control (l6 healthy

nonsmokers) . 54
Cigarette smoking, in addition to predisposing the
individual to lung cancer and emphysema, was reported to
transiently increase platelet aggregation, increase heart
rate and blood pressure, predispose the heart to
ventricular fibrillation, decrease oxygen carrying capacity
of hemoglobin, and raise fatty acid levels. 5•21

Therefore,

smokers tend to have lower HDL, and are more susceptible to
developing atherosclerosis and CHD particularly in female
smokers.
b.

Oral Contraceptives
Commercially available oral contraceptives contain

variable amounts of estrogen andjor progestin, both of
which seem to alter the lipid profile. 10 • 15 • 57 • 58

It has been

shown that plasma triglycerides and VLDL levels were higher
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in a majority of oc users compared to nonusers. 6 • 10 • 15
However, it seems that these two active ingredients have
different effects on the LDL and HDL component of blood
lipids and this difference appears to be dose-related.
Preparations containing low amounts of estrogen and medium
to high amounts of progestin appear to cause an increase in
LDL and a decrease in HDL.

On the other hand,

administration of conjugated estrogens significantly
increases HDL. 6 • 57 •59

Premenopausal. women who used oral

contraceptive products which are high in estrogen content
but low in the amount of progestin had higher levels of
HDL.

In contrast, postmenopausal women who used estrogen

had lower LDL concentrations compared to postmenopausal
nonuser controls. 5 • 58 •59
In women with a genetic disorder, plasma VLDL levels
increase dramatically when estrogen containing medications
were used.

Therefore, it has been recommended that plasma

cholesterol and triglyceride levels be measured before the
institution of oral contraceptives.

Documented findings of

hyperlipidemia may be considered a contraindication to the
use of these drugs. 15
c.

Alcohol Consumption
Several studies have addressed the effects of moderate

and severe alcohol intake on serum lipids and its
association with coronary heart disease. 60 - 62

Ethyl alcohol

consumption can produce a mild to severe elevation of VLDL
fraction which appears to be dose related. 5 • 15 • 61

Ethanol
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elevates the plasma triglycerides through inhibition of
fatty acid oxidation and by enhancing their hepatic
synthesis. 15

Chronic ingestion of large amounts of alcohol

may lead to pancreatitis, eruptive xanthomas, increased
blood pressure, and lipemia retinalis, especially in
patients with Type IV

hyperlipidemia. 6 • 15 • 62

It has been

demonstrated that moderate alcohol ingestion can lead to a
significant increase in HDL concentration and
subtraction without affecting HDL mass.

HD~

However, these

changes were significantly decreased when ethyl alcohol was
avoided. 60

It is important to point out that elevation of

HDL2 subtraction and HDL appear to be negatively associated
with CHD, while more dense
unrelated to CHD. 60 • 63 • 64

HD~

subtraction is reportedly

Moderate alcohol ingestion (30

gramsjday) was found to be associated with a significant
rise in

HD~

and no change in

HD~,

whereas high dose.s (60

gramsjday) were associated with a significant rise in
and HD~ subtractions. 61 • 63

HD~

The observed increase of HD~

and reduction of LDL levels in Taskinen's study 61 as well
as in animal models 63 was explained by an increase in
lipoprotein lipase activity (LPL).
will in turn increase both

HD~

and

Enhanced LPL activity
HD~

subtraction only

in chronic alcoholics but not in moderate alcoholics.

In

the animal model, lecithin cholesterol acetyltransferase
was addressed to be the key enzyme that is affected by
alcohol dose.

The enzyme activity was increased with

consumption of 12% calories from ethyl alcohol but
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diminished and markedly lowered with consumption of l8% and
24%, respectively.~

In a prospective study, moderate

alcohol consumption in middle aged female nurses was
associated with decreased risks of CHD and ischemic stroke
but was reported to increase the risk of subarachnoid
hemorrhage. 65

It appears that no single pathophysiologic

mechanism can explain all alcohol-induced changes in serum
lipids.

Alcohol consumption especially in excessive

amounts may increase the risk of hypertension, stroke,
cancer, pancreatitis, and liver disease.

The dangers of

acute and chronic excess alcohol consumption far outweigh
any possible or theoretical benefits from alcohol induced
elevated HDL or lowered LDL.

Therefore, alcohol should not

be recommended as part of any health program in the
prevention of CHD. 5
d.

Obesity and Physical Inactivity as Risk Factors
In obese people, the liver tends to increase the rate

of uptake of fats and carbohydrates from the intestine and
to increase mobilization of fat from adipose tissue.

This

high load of free fatty acids may activate increased
synthesis of VLDL, stimulate lipoprotein lipase activity,
reduce HDL level and increase LDL level. 5 • 6

Although its

contribution as an independent risk factor in CHD was not
well established, obesity causes an alteration in many CHD
risk factors.

Obesity has been found to be highly

associated with hypertension, glucose intolerance, and an
abnormal lipid profile.

Thus, extreme obesity (more than
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30% over ideal body weight) is considered a risk factor and
an important contributor to the risk of atherosclerosis and
CHn. 5 • 21 • 25 • 51 • 64

On the other hand, Leon, et al., showed

supporting evidence of the hypothesis that CHD and overall
mortality are inversely related to regular physical
exertion even in people with a high risk for CHD.~
Regular exercise activity was proved to be useful in
increasing the body's aerobic power, lowering heart rate
and blood pressure, raising HDL concentration, reducing
serum triglycerides, and decreasing body fat. 5 • 35

Although

its beneficial impact on CHD appears to be less than those
of the major risk factors, regular exercise is likely to be
beneficial as part of a comprehensive risk reduction
program. 5 • 35
e.

High Blood Pressure
Elevated blood pressure is directly related to the risk

of every major cardiovascular disease.

It is more

prevalent among blacks, elderly, obese, and oral
contraceptive users.

It has been reported that either

elevated systolic or diastolic pressure increases the risk
of CHD, although systolic pressure may be a better
predictor. 5 • 10 • 21 •35 • 67

High blood pressure has been found to

be a more reliable CHD predictor than the level of
cholesterol or cigarette smoking. 21

The Framingham study

documented the poor correlation between blood cholesterol
level and blood pressure (r=O.l2) . 67

However, a powerful

interaction was found to exist between high blood pressure
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and elevated blood cholesterol to produce CHD.

The higher

the blood pressure, the greater the probability of stroke
and CHD.

Serum cholesterol was found to be a strong and

graded risk factor over its entire distribution from 182
mgjdL and higher in men with high blood pressure. 10 •68
Further, it has been addressed that the risk of CHD
mortality at least doubled in hypertensive males who smoke
cigarettes. 68

Several techniques were suggested to control

elevated blood pressure, including weight reduction, salt
and caloric restriction, physical exercise, stress
reduction, and selecting antihypertensive medications with
minimal or no adverse effects on serum lipids. 51 • 67
f.

Diabetes Mellitus
Diabetes is a metabolic syndrome characterized by

symptomatic glucose intolerance.
females (2/3) than in males (1/3).

It is more prevalent in
Insulin-dependent

diabetics represent about 5-10% of the 4-5 million diabetic
population in the u.s .A. 18

Insulin is an important

substance in blood glucose regulation.

Low insulin level

or lack of its secretion causes an increase in blood
glucose due to decreased tissue utilization and increased
fat mobilization from adipose tissue.

As a result, a

significant increase in VLDL and chylomicron synthesis and
secretion in susceptible persons may occur.

In some

patients, there may be a slower rate of VLDL catabolism.
Controlling blood sugar by either diet, weight loss, or
drugs can reverse these abnormal lipid profiles.

However,
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a depressed HDL in patien"t:s w:i.::h non-insulin dependent
diabetes mellitus may not be corrected by controlling blood
glucose. 6

uncontrolled diabetes, on the other hand, has

been found to be associated with vascular disease and

,.,

increased risk of developing cno.'··

Hales with glucose

intolerance have about a 50% higher chance of developing
coronary artery disease (CAD) compared to males with no
glucose intolerance.

This effect varies widely based on

glucose level and thP. coexistence of othe:;:- rislc factors.
The lower the number of risk factors, the lower the risk of
CHD.

Diabetic females were reported to have double the

risk of developing CAD than diabetic males, even when
considering- the CAD rate differen=:e between males and

females.

It is important to remember that both

hyperlipidemia and hyperglycemia tend to be associated with
obesity and hypertension. 5 •21
Diabetics are more prone to a rapid progression of
cardiovascular disease including hypertension, congestive
heart failure, and CHD. 18

Atherosclerotic disease is still

considered the major cause of death in 75% of all North
American

d:~.abetics.

It has been postulated t.hat this high

death rate is due to microvascular and neuropathic
complications that lead to an extension of the
atherosclerotic process and subsequent peripheral vascular
disease; 5 • 18

These cardiovascular consequences of

uncontrolled blood glucose may depend on the level of
insulin, age of onset, etiology of the disease state, or
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adequacy and efficacy of nutritional and drug therapy. 5
g.

Drug-Induced Hyperlipidemia
Several studies have reported evidence of drug-induced

hyperlipidemia.

The most commonly reported drugs that may

induce an abnormal lipid profile include: thiazide
diuretics, beta blockers, nonsteroidal anti-estrogens,
corticosteroids, oral contraceptives, and retinoic acid
derivatives. 6 • 10 • 15 • 16

Allopurinol and some benzodiazepines

can significantly increase triglycerides. 32

Furthermore,

many studies have documented the potential adverse effects
of antihypertensive medication, in particular, on blood
lipids. 69 - 73

Thiazide diuretics were reported to

consistently increase total blood cholesterol (TBC) levels
by 4-13% and LDL by 7-29% compared to baseline levels.
This phenomenon appears to be dose related. 6 • 71

Short term

studies, however, have shown that the TBC/HDL ratio as well
as HDL concentrations are often unchanged. 70
Treatment with beta blockers, especially beta-1 and
non-selective agents with no intrinsic sympathomimetic
activity, also produce adverse effects on blood lipid
profiles.

This effect appears to worsen when these agents

are used in combination with thiazide diuretics. 6 • 70

In

addition, methyldopa has been reported to decrease HDL by
13-15%. 6

Among clinically used antihypertensive drugs,

pindolol, acebutolol, labetolol, guanabenz, hydralazine,
prazosin and calcium channel blocking agents appear to have
few or no effects on serum lipids. 6 • 71 • 72

In contrast,
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captopril in a dosage of 50 mg twice a day was found to be
associated with beneficial effects on serum lipids.

A

significant reduction of 101 mgjdL in triglyceride level,
50 mgjdL decrease in TBC, and 11% increase in HDL
concentrations were noticed.

Interestingly, these effects

disappeared when captopril was discontinued, suggesting a
cause-and-effect relationship.n

It has been concluded

that captopril has no significant harmful effects on serum
lipids. 57

Isotretinoin and etretinate were reported to

cause a significant increase in serum triglycerides and
cholesterol resulting in eruptive xanthoma and
pancreatitis.

The exact mechanism of such severe

lipoprotein changes is unknown, although VLDL and LDL
.

synthes~s

enhancement has been proposed. 6 ' 73

It should be remembered that treating one factor is
solving part of the CHD multifactorial problem.

Therefore,

screening for possible CHD risk factors and taking the
steps to correct them may be considered the initial step in
controlling CHD.
Screening for Hyperlipidemia
In order to initiate the steps toward controlling CHD,
the general public needs to be informed about the
significance of elevated blood cholesterol, its
relationship with CHD, and methods of prevention and
treatment available.

Identifying individuals who need

their cholesterol controlled is a crucial step toward the
control of CHD.

However, hyperlipidemia rarely produces
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symptoms until late in life when angina pectoris,
myocardial infarction, or heart attack could be the first
and the only symptom.~

At this point, treatment may not

restore the patient's original state of health but may halt
further deterioration and progression or complication of
coronary events.

Therefore, as stated by McKenney

" ... using symptoms to identify patients needing treatment
is not wise ... ~
For a screening program to be justified, the
following criteria must be met: 7
l.

The disease or condition must have

a

significant effect on the quality or quantity of
life.
2.

Acceptable methods of treatment must be
[

available.
3.

The condition must have an asymptomatic period

during which detection and treatment significantly
reduce morbidity or mortality.
4.

There are tests for this pre-symptomatic stage

that are reliable and acceptable in terms of risk,
cost, and degree of discomfort to the patients
5.

Treatment in the asymptomatic phase must yield

therapeutic results superior to that obtained by
delaying treatment until symptoms appear.
6.

Facilities are available for diagnosis and

treatment of those rated positive by the screening
test.

F
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Until recently, establishing programs to screen
cholesterol levels of large number of people was difficult
to establish in a practical way due to the length of time
and the high cost for each test.

To correctly identify and

subsequently treat individuals with high blood cholesterol,
accura t e an d

. .~ns t rumen t s are

prec~se

.

requ~re

d76
.

Now,

there are at least three portable analyzers available
whereby blood levels of different blood components can be
measured from a finger stick blood sample.n

The

technological advantages of these portable analyzers,
specifically those utilizing whole blood dry chemistry
reagents, have made cholesterol screening for the public a
reality.

In such cases, blood cholesterol levels can be

measured using approximately two drops of whole blood, and
the test result can be obtained in less than three minutes.
There was considerable variability between laboratories
in terms of accuracy of cholesterol measurement. 10 • 20 • 78 · 79
This situation restrained the national program intended to
control heart disease.

For this reason, the National

Cholesterol Educational Program (NCEP) and its Laboratory
Standardization Panel on Blood Cholesterol Measurement
developed recommendations to improve laboratory
performance. The following is a broad outline of the
panel's recommendations that were addressed to improve the
quality of cholesterol measurement:n
1.

Clinical laboratories in the United States

should employ uniform cholesterol outpoints for
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identifying adults at high risk for CHD.
2.

Laboratories must minimize method-specific bias

and also achieve adequate precision of cholesterol
measurement.

This includes particular attention to

method/instrument and calibration procedures.
3.

A deviation from the true cholesterol value of

a standard sample (bias) should not exceed plus or
minus 5% from the true value and should not be
greater than plus or minus 3% from the true value
within five years.
4.

All newly available portable chemistry

analyzers for cholesterol measurement need further
evaluation before they are adopted for routine use
with patients.
5.

Proper training of technical personnel in the

use, maintenance, and quality-assurance procedures
are necessary.
6.

All clinical laboratories' measurements in the

U.S.A. should and can be standardized so that their
values are traceable to the Center of Disease
control (CDC) reference method or to the National
Bureau of Standards definitive method.

This may be

achieved by utilizing certified reference
materials.
7.

To achieve adequate blood cholesterol

measurements and to minimize the effect of
interfering substances, modifications in reagents

f
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andjor instruments may be necessary.
Serum cholesterol can be measured using an enzymatic
method based on cholesterol esterase and oxidase reaction
as in the case of the DuPont ACA and the Reflotron
instruments or by the more economic colorimeteric assay. 10
Several studies have recently evaluated precision,
accuracy, and bias associated with the use of the new
portable desk top analyzers used for measurement of
TBC. 76 • 77 •80 •81

It has been concluded that the use of these

instruments, when operated according to the manufacturer's
recommended procedures, demonstrated acceptable accuracy
and precision that met those goals established by the NCEP.
The characteristics of the three most commonly used
instruments for large cholesterol screening programs are
presented in Table III. 77
In spite of the inconclusive establishment of the
proper age at which screening for hyperlipidemia (HLP)
should be initiated, most screening tests are done after
puberty. 49

It has been recommended that individuals with a

family history of hypercholesterolemia and those with
xamthomas, pancreatitis, or very premature CHD in first
degree relatives be screened before puberty.

On the other

hand, those individuals with documented CHD in first degree
relatives, women on oral contraceptives, most American men,
and those with established risk factors should be screened
between the age of 20 to 25.

Lastly,

everyone 20 years

and older should check hisjher blood cholesterol level

r

~

----1
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Table III:
Accuracy study:l Cholesterol Testing of Three Office
Chemistry Instruments Compared With LRC2 Results Using
NCCLS 3 Guidelines for Method Comparisons.

Instrument N

Mean 4 Slope
mgjdL

Y-Intercept
mg/dL

r

SE 5 Total
mgjdL Bias %

83 223

l . 06

1

0.98

12

+ 3.9

Boehringer 83 225
Mannheim
Reflotron

0.79

18

0.97

13

+ 4.5

Kodak
Ektachem
DT 80

0.9

20

0.98

10

- 1.8

Abbott
Vision

83 211

1 Adapted from Reference #77, p.3446.
2Lipid Research Clinic.
3 National Committee for Clinical Laboratory Standards.
4LRc Mean equals 215 mgjdL.
5standard Error.
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every five years and more often if the patient is obese,
smoker, hypertensive, or diabetic. 49
Albeit the intensive effort of the NCEP to encourage
the public to know their cholesterol level, only 29-57% of
adults have had their cholesterol checked nationwide. 39

In

fact the month of April 1988 was denoted as "National Know
Your Cholesterol Month" in recognition of the need for
federal, state, and local activities to support cholesterol
awareness.

Health care providers are encouraged to take

the initial steps to inform their patients of their
cholesterol value and what it means. 39
Special attention should be paid to four subgroups in
which it is wise to monitor and treat HLP, even with no
significant elevation in serum cholesterol.

The first

category includes post coronary bypass patients where
angina and new vein graft occlusion reoccur in a
predictable number of them.

The second category consists

of patients on chronic renal dialysis, where
atherosclerosis is often markedly accelerated.

The third

category represents patients with Tangier disease, a rare
disease where HDL is almost totally absent.

The fourth

category includes patients with moderate or severe elevated
triglyceride levels, particularly in those with hereditary
deficiency of lipoprotein lipase (Type I & V phenotype). 49
What Lipoprotein Fraction Should Be Measured?
For screening purposes, it has been recommended to
measure total blood cholesterol (TBC} in a non-fasting
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state.

Many studies have shown that high levels of LDL and

TBC are strong risk factors for atherosclerosis and
CHD. 7•18

Although LDL is the actual target of cholesterol-

lowering efforts, TBC can be used instead during the
initial screening tests.

The use of TBC as a screening

tool is more available, less expensive, and does not
require the patient to fast for 10-12 hours before the
test.

Furthermore, it has been demonstrated that both

fasting and non-fasting measurements of TBC are equally
reliable. 4 • 18 •20 • 75 • 82 • 83

In addition, it has been reported that

TBC is not altered by the cholesterol or triglyceride
content of meals, and therefore, there is no reason to use
any other measure of blood lipids initially. 7 • 18 •20 • 75 •82
When screening individuals for elevated blood
cholesterol, the objective is not simply to label or
classify the patients but rather to take preventive
measures early in the disease state.

Advancing the time of

diagnosis, through initial TBC screening and referral
procedures, might have a desirable prognostic value.

The

effectiveness of such procedures can be enhanced if
effective therapy could be started during the asymptomatic

period.~

Therefore, it is advocated that screening tests

may have the potential to advance the time of diagnosis
since survival is measured from the time of diagnosis
rather than the time of onset.

Mully~ concludes that

" .•. the survival of patients whose diseases are detectable
by screening should be expected to be longer than that of

38

patients who present symptomatically."

In addition,

patients at risk of CHD who spend more time in the
asymptomatic period, are more likely to be identified by
screening tests than are patients with more aggressive
disease, added Mully.

It is important, however, to note

that screening results should not be considered as
definitive diagnostic tools.
Several considerations must be made before labeling
patients with either high, normal, or low blood
cholesterol.

Diagnostic evaluations based on the

lipoprotein pattern rather than TBC level was suggested to
enhance sensitivity and specificity. 14

Labeling

individuals may produce its own morbidity and negative
effect on health perception.

Furthermore, labeling can

also have a negative outcome on employability and
insurability.~

Since the treatment of HLP, either by

dietary means or drug therapy can be life-long, expensive
and sometimes exposes the patient to potentially hazardous
side effects, it has been recommended to accurately
evaluate patients for underlying risks of developing CHD
including assessment of life style and drug andjor disease
state influence.
In a study involving 8449 subjects intended to evaluate
the efficacy of screening for dyslipoproteinemia (both
hyper- and hypolipoproteinemia), it was found that more
than 80% of all the hyperlipidemic participants had
hyperlipoproteinemias.

It was concluded that such lipid
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screening provided a lower proportion of false-positive
than false-negative results.

In addition, most

participants (>98%) without hyperlipoproteinemia (true
negative) were correctly identified. 14
General Versus Selective Screening
Selective screening may not serve as a sufficient means
of reducing the incidence of CHD.

This may be true since a

large proportion of individuals at risk would not be
examined if assessment was restricted to a targeted
population with preestablished selected screening criteria.
In addition, testing the cholesterol level as part of any
first attendance medical examination (case finding
approach) has been recommended to be the usual approach. 20
The overall goal of both the general screening and case
finding approach is to recognize people with high levels of
risk factors who require treatment. 53

It has been

emphasized that"··· detection of increased risk implies a
commitment to provide continuing preventive care. " 53
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Treatment of Hyperlipidemia
In spite of the extensive clinical data and
epidemiologic evidence linking elevated blood cholesterol
levels to CHD, some doubt and controversy remains about the
strength of the causal relationship between the two
parameters. 2•4 •6 • 16 •85

The National Institutes of Health (NIH)

and the National Heart, Lung, and Blood Institute (NHLBI)
assembled a consensus conference on lowering blood
cholesterol to prevent heart disease held from December 1012, 1984. 2

This conference was initiated to investigate

the link of increased CHD with increased blood cholesterol,
and to resolve the questions related to when to treat high
blood cholesterol, and what should be done to diagnose such
levels.

This consensus panel met after the results of the

Coronary Primary Prevention Trial had shown that "lowering
blood levels of cholesterol actually has reduced the risk
of heart attacks".

This panel represented experts in a

variety of disciplines including;

cardiology,

epidemiology, biostatistics, and experts on diet and
nutrition, preventive and primary care medicine.

The

expert panel's goal was to get a consensus position on
important and crucial questions.
raised were the following:
1.

Among the questions

2 20 85
• •

Is there a causal relationship between blood
cholesterol level and CHD?

2.

Will reduction of elevated blood cholesterol help
prevent CHD?
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3.

How and when should dietary and drug therapy be
started?

4.

And under what circumstances?

What are the goals of treatment?

After hearing a series of presentations and reviewing all
clinical and epidemiological data, the 1984 panel concluded
that:
a.

Elevated blood cholesterol is a major cause of CHD.

b.

Lowering high cholesterol level (especially LDL) would
help, beyond any doubt, in reducing the risk of CHD.

c.

Everyone with a blood cholesterol level above the 75th
percentile (at or above 240mg/dL) is recommended to be
treated. 2 • 85

d.

Dietary change under the guidance of a physician,
dietitian, or other health professional is the primary
treatment for high cholesterol.

If response to diet is

not adequate, appropriate drug therapy should be added.
e.

Since blood cholesterol levels of most Americans are
undesirably high, which in large part is due to a large
dietary intake of saturated fat and cholesterol, all
Americans two years and older were advised to reduce
their total fatty intake from the current level of 40%
to 30% of total calories.

Further, it recommended

reducing saturated fat to less than 10% and increase
polyunsaturated fat by no more than 10% of total
calories, and reducing dietary intake of cholesterol to
250-300 mg or less daily.
f.

Special attention should be paid to identify and manage

42

other underlying risk factors such as hypertension,
cigarette smoking, diabetes, and obesity.

It is

important to point out that the NIH consensus panel
guidelines 2 used to classify patients with blood
cholesterol levels at the 75th and 90th percentiles
based on patient's specific age {See Table IV (A)).
To establish a detailed set of new guidelines that
provides practical advice for dealing with the adult
patient's cholesterol problem, the National Cholesterol
Education Program (NCEP) asked a panel of experts in 1987
to develop new guidelines for detection and management of
high blood cholesterol. 85

The panel, which included

experts representing a variety of disciplines and a wide
range of expertise, worked for over a year to establish a
consensus position on additional questions.

Cleeman

reported a list of these questions that included " ... how to
go about detecting and evaluating high blood cholesterol,
at which levels of cholesterol to initiate treatment, what
the goals of treatment are, how to use dietary therapy, and
how and when to use drug therapy in addition to diet. ,as
This major panel carried out its work through three
subcommittees, namely,

(1) the subcommittee on prevalence,

detection, diagnosis and evaluation;

(2) the subcommittee

on dietary treatment; and (3) the subcommittee on drug
therapy.

The report of the expert panel on blood

cholesterol in adults was first published in January 1988,
representing a true and highly collective agreement

I
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Table IV (A}:
NIH1 Guidelines on Total Blood Cholesterol 2 (1984}.

Assigned Risk of Coronary Heart Disease For Cholesterol
Age

Moderate Risk

High Risk

20-29

> 200 mgjdL

> 220 mg/dL

30-39

> 220 mgjdL

> 240 mg/dL

> 240 mgjdL

> 260 mg/dL

40 and over

1National Institutes of Health.
2 Adapted from Reference #2, p.2083.

Table IV (B):
NCEP1 Guidelines Based On Total Blood Cholesterol 2 (1987).

Desirable
Blood Cholesterol
< 200 mgjdL

Borderline-High
Blood Cholesterol

High
Blood Cholesterol

200-239 mgjdL

240 mgjdL & Above

1 National Cholesterol Educational Program.
2Adapted from Reference #20, p.37.
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posl.'t.l.on. 85

The panel recommendation is applied to any

person who is 20 years and older regardless of sex.

20 29 85
• •

These guidelines include the following characteristics:
l.

The cutoff point at which interventions should be
initiated is a total blood cholesterol of 200 mgjdL or
higher.

2.

Total blood cholesterol is used for initial case
finding (screening) and monitoring the progress of
dietary therapy, while LDL is used thereafter to refine
the assessment of CHD risks and for establishing the
final diagnoses.

3.

The individual's overall risk of CHD must incorporate
additional risk factors other than TBC level which
influence the choice of cut points and goals of
cholesterol targeted levels.

4.

Cut points and specific goals for drug therapy are
established that protect from overuse of lipid lowering
drugs to achieve a cholesterol level that could have
been reached by diet alone. 19

The NCEP expert panel

report includes additional information dealing with an
educational effort directed to all health care
professionals including physicians, pharmacists, and
dieticians.

Furthermore, an overview and summary of

classification, prevalence, detection, and evaluation
of elevated blood cholesterol, evidence and magnitude
of the link between high cholesterol and CHD and a
step-wise approach of dietary and therapeutic treatment
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are also presented. 20
For initial screening of blood cholesterol, a non
fasting state is recommended by the expert panel.
Individuals are to be classified into one of three classes
based upon their cholesterol level {See Table IV (B)}.

A

cholesterol level below 200 mgjdL, regardless of age or
sex, is considered "desirable or normal".

Persons within

this class are advised to repeat their cholesterol test
within 5 years from the initial screening and be assessed
for other CHD risk factors and be given dietary and risk
reduction information.

A borderline-high blood cholesterol

is referred to as blood cholesterol level of 200-239 mgjdL
that needs to be rechecked annually.

Patients in this

second category who do not have a history or evidence of
heart disease and/or less than two risk factors should be
advised to start a "step-1 11 diet.

The goal of such dietary

therapy is to minimize the consumption of saturated fat to
less than 10%, cholesterol to less than 300 mgjdL, and
increase the carbohydrate intake to 50-60% of total
calories.

Total blood cholesterol should be checked at 4-6

weeks and at three months after starting the step-1 diet to
assess dietary intervention.

If dietary goals have not

been achieved, lipoprotein analysis should be initiated to
determine LDL level.

If the LDL level is found to be

normal (less than 130 mg/dL), the patient should be advised
to maintain a prudent diet and reduce controllable risk
factors such as elevated blood pressure, cigarette smoking,

F
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and high blood sugar.

The patient is then advised to

recheck his/her total blood cholesterol quarterly for the
first year and twice yearly thereafter. 20 •24

There are two

options for people who have borderline-high blood
cholesterol who failed the step-1 diet.

Hejshe may be

referred to a registered dietician to either retry this
step-1 diet or start the step-2 diet (See Table V), based
on clinical and risk factor considerations.
then remeasured in 3-6 weeks and at 3 months.

Cholesterol is
Patients at

high risk of developing CHD, TBC of more than 240 mgjdL or
borderline-high risk plus definite heart disease andjor two
additional risk factors, including male sex, should have a
lipoprotein analysis done.

In addition, a complete family

history and clinical evaluation including screening for
secondary causes (drug andjor disease induced) of
hyperlipidemia (HLP).
If LDL level was found to be normal, TBC should be
repeated every five years and dietary and risk reduction
information should be provided.

In contrast, if the

patient was found to have a borderline-high LDL (130-159
mgjdL) with no heart disease or less than two CHD risk
factors, a step-1 diet and the subsequent algorithm
outlined above should be initiated and TBC should be
evaluated annually.

On the other hand, if the patient was

found to have high risk LDL (160 mgjdL or higher) or has
definite heart disease andjor two risk factors, a complete
clinical evaluation should be started.

Based upon the

I[!
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Table

v:

Dietary Therapy of High Blood Cholesterol Level. 1

Recommended Dietary Intake
Nutrient

Step-One

Step-Two

Total Fat
Saturated
Polyunsaturated
Monounsaturated

< 30% of tc2
< 10% of tc
Up to 10% of tc
10-15% of tc

< 30% of tc
< 7% of tc
Up to 10% of tc
10-15% of tc

Cholesterol

300 mgjdL

< 200 mgjdL

Carbohydrate

50-60% of tc

50-60% of tc

Protein

10-20% of tc

10-20% of tc

Total Calories

to achieve and maintain desirable weight

1Adapted from Reference #20, p.46.
2tc= Total calories.
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patient's total blood cholesterol, LDL, coronary risk
profile, clinical status, age and sex, initiating a
selective hypolipidemic drug therapy should be considered.
For patients with borderline-high risk who have
definite CHD or two risk factors as well as high risk
groups, the goal of therapy is to lower LDL to below 130 mg
and 160 mgjdL, respectively.

The two dietary steps

recommended by the panel in their report are very similar
to dietary modifications recommended by the American Heart
Association. 20

These diets are designed as part of a

population-based program to progressively reduce the intake
of saturated fats and cholesterol and to eliminate excess
calories (See Table IV) . 5 • 20

It has been emphasized that

physicians should let their patients understand that the
goal of dietary therapy is not a temporary diet, but rather
a permanent change in their eating behavior. 20

A schematic

approach of classification, evaluation, and step-wise
treatment approach based on TBC and LDL levels is presented
in Figures 2 and 3. 20
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Measure Total
Blood Cholesterol
•
•

Every Adult
Nonfastlng

Assess Other
Nonllpld CHD
Risk Factors

Classification
<200 mg/dl

Desirable Blood Cholesterol

200·239 mg/dl

Borderline-High Blood Cholesterol

2240 mg/dl

High Blood Cholesterol

Recommended Follow-up
Total Cholesterol <200 mg/dl

Repeat within 5 years

Total Cholesterol 200·239 mg/dl
WITHOUTdeflnlte CHD
or two other CHD risk
factors (one of which
can be male sex)
WITH definite CHD
or two other CHD risk
factors (one of which
can be male sex)

Dietary Information and
recheck annually

Lipoprotein analysis;
further action based on
LDL-cholesterol level

Total Cholesterol 2240 mg/dl

Figure 2:

Initial Classification and Recommended Followup Based
on Total Cholesterol. (Adapted from Reference #20).
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Do Lipoprotein Analysis:
•

12 hour fast
Measure total cholesterol, HDL·cholesterol, and
trlglycerldes
Estimate LDL-cholesterol=
total cholesterol - HDL·cholesterol - (triglycerldes/5)
Average of 2 to 3 measurements, 1 to 8 weeks apart

Classification
<130 mg/dl

Desirable LDL·Cholesterol

130·159 mg/dl

Borderline-High-Risk LD L·Cholesterol

~160

High-Risk LDL·Cholesterol

mg/dl

Dietary Treatment
Initiation Level

Minimal Goal

WITHOUT CHD or two other
risk factors

~160

mg/dl

<160 mg/dl

WITH CHD or two other
risk factors

~130

mg/dl

<130 mg/dl

Drug Treatment
Initiation Level

Minimal Goal

WITHOUT CHD or two other
risk factors

~190

mg/dl

<160 mg/dl

WITH CHD or two other
risk factors

~160

mg/dl

<130 mg/dl

Figure 3:

Classification and Treatment Decision Based on LDLCholesterol (Adapted from Reference #20).
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Dietary Fish and Fibers
It has been observed epidemiologically that
cardiovascular mortality in Greenland Eskimos and the
Japanese is relatively lower than that of the Western
industrialized world. 86 •87

This difference is believed to be

related to the protective effects of their diet which
consists mainly of fish and marine foods in general.

It is

well known that most marine foods contain large quantities
of omega-3-fatty acids, namely, eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA).

Several reports pointed

out the beneficial effect of omega-3-fatty acid consumption
on cardiovascular disease. 6 • 20 •86 •87

These reports

demonstrated that these fatty acids can decrease
triglycerides and cause a small decrease (or sometimes
increase) in LDL cholesterol with no effect on HDL. 88
However, it has been reported that "No studies are
available either comparing the effectiveness and safety of
fish oil with other lipid-lowering drugs or showing that
fish oil causes regression of atheromata or decreases the
incidence of coronary heart disease.

1188

several mechanisms have been proposed for the potential
beneficial cardiovascular effects of fish oil.

The

following are the major mechanisms proposed:
1.

Reducing the hepatic VLDL and fatty acid synthesis.

2.

Increased VLDL elimination.

3.

Enhanced fecal steroid excretion.

4.

Interfering with platelet aggregation which plays a

52
key role in thrombosis and promotion of arterial
smooth muscle cell proliferation.
5.

Alteration of monocytes and neutrophil function,
thereby prevent formation of fatty streaks and
fibrous plaque formation.

6.

Reduction in blood pressure in patients with mild
hypertension.

It is important to keep in mind that fish oil
consumption, especially in large amounts, may cause
bleeding due to decreased platelet aggregation and
increased bleeding time and, therefore, should be used with
caution, if at all, in patients on anticoagulants or those
with an active bleeding condition.

This seems to be in

accord with what has been reported in that Eskimos have a
twofold higher incidence of stroke than citizens of Western
countries. 29 • 87

In addition, ingestion of large amounts of

certain fish oils may contain toxic amounts of vitamin A
and D.

Overall, however, fish in general is considered a

useful substitute for meats (which are rich in saturated
fats) and may be of value in lowering triglyceride and
cholesterol levels with minimal harmful side effects.
Dietary ingestion of approximately 15-25 gramjday of
soluble fibers was reported to be associated with a 5-15
mgjdL reduction in plasma cholesterol. 20

oat products and

beans, which contain a beta-glycan gum, pectin, and
psyllium (e.g., Metamucil) were found to possess similar
effects on blood lipids. 20 • 89 • 90
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In a double blind, placebo-controlled parallel study,
the effect of Metamucil (which contains 79% psyllium
hydrophilic mucilloid) was found to reduce total blood
cholesterol (TBC) by 14.8%, LDL level by 20.2%, and the
ratio of LDL/HDL by 14.8% compared to baseline values. 89
This effect was seen in response to 3.4 grams of psyllium
three times per day for eight weeks, after a two-week
baseline period.

Impressively, psyllium treatment had no

significant effect on body weight, blood pressure, HDL,
triglycerides, or blood glucose.
Short term effects of psyllium supplements was reported
to lower TBC by about 16%, while long term effects of
dietary fibers from oat and bean reduced blood cholesterol
by more than 20% and this effect was reported to last for
at least 2 years in hypercholesterolemic men. 91

In the

Fagerberg study, 90 Metamucil was reported to possess a safe
and long acting effect on fasting blood glucose and serum
cholesterol.
Although these clinical studies documented the
hypoglycemic and hypolipidemic effects of soluble fibers (a
20-30% reduction in TBC), the American Heart Association
diet (which lowers TBC by 3-7%) does not include dietary
fiber as an approach to lowering blood cholesterol.

on the

other hand, some experts still question dietary fiber
usefulness as a therapeutic modality. 91

However, it has

been reported that patient compliance with dietary fiber
treatment was excellent with no observed clinically
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important side effects.
Drug treatment
It is to be emphasized that treatment of HLP by dietary
means remains the cornerstone in the management of patients
with elevated lipids.

Dietary therapy should be tried for

at least six months, or for 12 months if indicated by a
physician, before considering drug treatment.

This is

because drug treatment can be tedious, lifelong, involves
cost to patients, and poses potentially hazardous side
effects.

Therefore, consequences of anti- hyperlipidemic

medication should be considered before starting drug
therapy.

Characteristics of drugs used to treat high blood

lipid are presented in Table VI. 24

The bile acid

sequestrants (cholestyramine and colestipol) and nicotinic
acid are considered the drugs of first choice in the
management of hyperlipidemia.

These two drug categories

lower the risk of CHD in clinical trials as well as have
established long-term safety. 20

If used in the recommended

dose, a 15-30% reduction in LDL level is expected.

These

two categories require considerable patient education in
terms of how to take the drug and what to do to reduce the
risk of side effects to improve patient compliance.

It has

been reported that bile acid sequestrants are often
associated with increased triglyceride levels (equal or
more than 250 mg/dL) due to increased hepatic VLDL
synthesis.

Therefore, in patients with concurrent

hypertriglyceridemia and hypercholesterolemia, nicotinic
~

~--

'
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Table VI:
Characteristics of the Hypolipidemic Drugs.l
Agent

(Brand Name)

Chol es tyramine

Effect on Reduced risk Long-term
lipoprotein
of CH0 2
safety

Oec 5 LDL

Yes

Yes

(Quest ran)

Maintaining X Lowering
ac:tlerence

r

LOL 3

Daily

Cost

dosage

($)

4

15-30

12·16g

57.60

15·30

15·30 9

41.07

15-30

3·6 9

58.82

25-45

40-80 mg

46.88

1200 mg

41.63

1-2 9

44.20

1 9

45.50

R~ire

Colestipol
(Colestid)

Dec LDL

Nicotinic Acid

Dec LDL,

(Nicotar)

lnc 6 HDL 7
Dec VLOL 8

Lovastatin
(Mevacor)

Dec LDL,

Not

Not

Inc HDL

proven

established

Gemfibrozi l

Dec LDL,

Yes

Yes

(Lopid)

Inc HDL

Yes

Yes

considerable
pat lent
education

Yes

Yes

j

I

5·15

Relatively
easy

Clofibrate

Dec VLDL,

CAtromide-S)

May Inc

Not

proven

Not

established

HOL

Prlbucol

Dec LOL,

(Lorelco)

Dec HDL

Not

proven

No effect
on LDL

Not

established

10·15

lAdapted from References 16, 24, 35, and 88.
2 coronary Heart Disease.
3 Low density lipoprotein.
4 cost to pharmacist for 30 days' treatment.
5oec=Decrease.
6rnc=Increase.
7HDL=High density
8 VLDL=Very low density lipoprotein.
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acid is the drug of first choice.
The 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase
inhibitor (HMG-Co A), lovastatin, is a new member of a
class of drugs that has been classified as a second line
for treatment of lipid disorders.

They are effective in

lowering LDL (25-45% reduction), increasing HDL with an
excellent level of compliance.

Since this drug category is

relatively new, its effectiveness in preventing or
reversing atherosclerosis and CHD as well as its long-term
safety have not yet been established. 20

However,

lovastatin (in 20 mg and 40 mg twice daily) in a 12-week
study in 264 patients has been shown to be more effective
in lowering LDL and TBC and better tolerated than
cholestyramine (12 grams twice daily) . 92
Gemfibrozil (Lopid) is a drug that belongs to the
Fibric acid category which is effective in lowering plasma
triglycerides and VLDL while increasing HDL.

In a recent

five year blind trial (the Helsinki Heart Study) , Lopid has
been shown to decrease triglyceride and LDL levels and
increase HDL in 4, 081 asymptomatic men. 83 •93

This study has

proven the effectiveness of the drug in decreasing the
number of myocardial infarctions (56 in Lopid group vs. 84
in placebo group) and therefore, is associated with low
incidence of CHD.
Probucol (Lorelco) and clofibrate (Atromid-S) are
primarily effective for lowering triglyceride levels.
However, probucol may decrease HDL in addition to its
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significant side effects.

Clofibrate may increase LDL,

decrease libido, and increase gallstone and tumor
formation.

Therefore, these two drugs are not yet approved

by the Food and Drug Administration for routine use in
lowering elevated blood cholesterol levels and are
considered to be last resort drugs.
Community-based Cholesterol Screening
A community-based cholesterol education program should
give high priority to the goal of detection and
intervention.

However, in the past, several barriers to

this goal have existed. 94

These barriers include the

necessity for venipuncture by trained personnel to obtain
blood samples, the expense of laboratory tests, the delay
between sample collection and receiving the test results,
and the lack of standardization for cholesterol
determination across clinical laboratories.

Fortunately,

new guidelines were recommended in 1987 and new cholesterol
values were clearly established.

Furthermore, patient

education material and affordable and accurate portable
equipment became available to facilitate community-based
cholesterol screening programs.

Nevertheless, with these

more restricted guidelines, a majority of individuals would
be expected to experience ·difficulties with adherence to
these guidelines or goals.~
Two pilot community-based cholesterol determination
studies utilized the portable Kodak analyzer (EKTACHEMDT60) where the blood sample was collected from a finger

F
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puncture. 94 • 95

In the Lefebvre 94 cholesterol screening and

education campaign, 1439 participants were recruit.ed
through extensive media coverage from March to April 1985.
It was reported that nearly 60% of recruited individuals
were found to have blood cholesterol levels that exceeded
recommended goals (TBC < 200 mgjdL).

A series of

cholesterol Screening, Counseling and Referral Events
(SCOREs) were conducted several times weekly during the two
month campaign.

Cholesterol screening events were

conducted in 21 sites including several churches, shopping
plazas, local businesses, local area drug and retail
stores.

Two months from the initial screening, three

hundred ninety nine individuals (27.7%) individuals had not
returned for the second cholesterol measurement.

Nearly

sixty percent (57.69%) of the remaining 1040 persons had
successfully reduced their blood cholesterol by an average
of 29.1 mgjdL.

In contrast, 423 persons (40.67) had an

increase in blood cholesterol and additional 17 persons
(1.63%) had no changes.
The second study was conducted in the New York
metropolitan area and lasted five days. 95

At the end of

the study period, 12,432 participants had been tested at
six sites including five hospitals and a health education
facility.

Approximately half the population reported that

they had their cholesterol checked previously.

Three

hundred participants from the original screening were
contacted by a telephone survey.

Eighty eight claimed that
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they saw their physicians (29.3%), however 57% of them
reported that their physician did not measure their
cholesterol again to confirm the initial screening results.
Unfortunately, 54% of respondents received no advice from
their physicians, while 36% reported that dietary changes
were recommended.

Surprisingly, 71% of individuals with

cholesterol levels between 221-260 mgjdL were advised to do
nothing and not to worry. 95

This indicates the need for

cholesterol education programs which must be directed not
only to the public but also to physicians.

Referrals for

lipoprotein analysis and initiation of dietary or lipidlowering drug therapy would be a major problem if
physicians are not taking the appropriate steps to bring
their patients' blood cholesterol down to acceptable
levels. 94
Several studies demonstrated the possibility of
implementing community screening programs that targeted
toward motivating more people to become aware of their
cholesterol levels. 96

Educational programs should be

targeted toward providing those with high serum levels the
necessary information to help lower their cholesterol.
General dietary recommendation, food selection, and follow
up protocols to assess patient response to dietary changes
and lowered cholesterol level has been emphasized.

r=
l

r-
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Scope Of The Study
It was pointed out that the availability of accurate
and portable blood cholesterol measurement equipment, that
utilizes blood obtained from a finger stick, facilitates
screening efforts, especially for pharmacists. 32

Several

advantages were reported to be associated with such health
care program at community pharmacies.

First, pharmacies

have a wide geographic distribution and are easily
accessible.

Second, pharmacists can provide professional

information and provide educational materials that enhances
the screening effort.

Third, they can establish referral

and monitoring programs for those patients with
hyperlipidemia and counsel patients on side effects of
drugs, if prescribed.

This enhances the pharmacist's long-

term contribution in controlling high blood cholesterol and
CHD morbidity.
It has been reported that total blood cholesterol
screening in a community pharmacy may be an important new
opportunity in pharmacy practice.

Providing such screening

service offers pharmacists a unique opportunity to expand
their patient-oriented clinical services which may prove to
be a financially feasible public health activity. 29 •97 "99
Pharmacists can improve the public's awareness and
understanding of the importance of lowering blood
cholesterol.

It remains to be determined if screening with

long-term follow up in a community pharmacy is, in fact,
effective.

I
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This current research project was initiated to
investigate the feasibility and outcomes of conducting a
cholesterol screening program in a community pharmacy.

It

was targeted toward identifying individuals with elevated
blood cholesterol levels and helping them control their
levels.

Follow up procedures, pre- and post-test survey,

CHD risk factors assessment, and medication screening were
considered as an integral part of the study.

This project

was also intended to evaluate the impact of this new
patient oriented community service in terms of TBC level
lowering and behavior changes.

Acceptability of the

project to the participants and willingness to pay for the
proposed service if it were to be available in their
community pharmacy was also evaluated.

Long term follow up

and referral service following the initial screening was
investigated to determine its effectiveness.

62

GOALS AND OBJECTIVES
Goals:
1.

To develop a model for screening, detecting,

and referring ambulatory patients with elevated
blood cholesterol in a community pharmacy.
2.

To increase the patients' awareness and

understanding of the value of lowering their blood
cholesterol and its impact on the morbidity and
mortality of coronary heart disease (CHD).
3.

To establish a follow up procedure for those

patients at high risk of developing CHD.
4.

To identify patients with multiple risk factors

and to encourage them to see their primary health
care provider to establish the final diagnosis and
adherence to treatment regimen, if indicated.
5.

To provide motivation for patients with high

blood cholesterol to lower their levels below 200
mgjdL.
6.

To assess patients' acceptance of the model,

its convenience, and potential utilization of
screening procedures in a community pharmacy.
Objectives:
1.

To investigate the role of a community

pharmacist in screening and follow up of ambulatory
patients for hypercholesterolemia in a community
pharmacy.

r
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2.

To define criteria for the selection of the

patient population accepted in this study.
3.

To identify those patients with elevated blood

cholesterol who require further evaluation,
monitoring andjor treatment.
4.

To provide appropriate educational material for

all participants screened and answers to their
questions about cholesterol and other related
issues particularly those at high risk of
developing CHD.
4.

To determine the impact of this project on:
a. The patients' awareness of the problem.
b. Lowering blood cholesterol during the follow up
period.
c. The degree of participants' acceptance of the
idea of screening cholesterol level in a
community pharmacy.
d. Participants' attitude in terms of convenience
and future utilization of such service if it
were to be available in their community
pharmacies.

t

METHODOLOGY
General Description
This community pharmacy screening project was designed
in an attempt to identify individuals with elevated blood
cholesterol.

Patients classified at moderate or high risk

for developing CHD would be referred to their physicians
for further evaluation and treatment.
At the time of the initial screening, a brief personal
and family history was collected to assess those patients
with potential risk factors for developing CHD.

These

collected data were used to identify those patients who
were in need of referral and monitoring services.
Follow up blood cholesterol testing during the five
month period allowed assessment of patients' serum
cholesterol status and response to dietary and exercise
changes.

It also allowed the pharmacist to screen patients

for potential drugs that could induce or exacerbate
hyperlipidemia.

I

Follow up visits served as an appropriate

time to provide additional teaching and counseling.

Test

results at the initial screening without subsequent follow
up testing might needlessly worry patients.

Motivating

those patients with multiple risk factors to see their
physicians was emphasized as the determining step in
controlling their high cholesterol level.
The study protocol and the consent form (See Appendix
A) were approved by the University Joint Council on Human
64
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Research.

The project's screening procedures, patient

interviews, referral service, and follow up testing were
conducted in the Campus Pharmacy, University of the
Pacific, Stockton, California.
Identification of Patients
a.

Subiect Recruitment
Two hundred and forty-one persons, including University

of the Pacific students, faculty, and employees were
screened for high blood cholesterol (200 mgjdL or more).
Subjects were recruited through two advertisements in the
University newspaper (The Pacifican) and signs posted
around the campus.
For screening· purposes, total blood cholesterol (TBC)
was measured in a non-fasting state.
b.

Inclusion Criteria
Patients were admitted to the study if they met the

following inclusion criteria:
1. Participants must be between 18 and 60 years of
age.
2. Participants must not know their cholesterol
level and have not been told by a physician that
they have high cholesterol level.
3. Patients must not be receiving cholesterol
reducing· agents.
4. Participants must not be dieting or exercising
already to reduce cholesterol levels.
5. Participants must be available for f-ollow-up
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during the six month period of the study.
6. Participants must be ambulatory.
7. If female, participants must not be pregnant.
8. Participants must not be involved in other
concurrent studies.
All participants with an initial TBC of < 200 mgjdL,
the "Normal Group" were excluded from subsequent blood
testing and were given educational materials on maintaining
good eating habits and exercise level.

They were advised

to check their TBC within the next five years and to keep a
record of their test results.

Since blood sampling is an

invasive procedure, a written informed consent form was
provided to each participant.

Two consent forms were used,

the first was required by the University committee on Human
Research and the second was a release of liability
requested by Boehringer Mannheim Diagnostics.

After

explaining the scope of the project, procedures involved,
and accompanying hazards that might occur, each participant
was asked to read the provided consent form and sign it,

A

carbon copy was given to each participant with the TBC test
result at the initial visit.

All participants were advised

that the initial TBC test as well as the two subsequent
follow up tests, when applicable, were free of charge.

No

fees were paid for any individual to participate in this
study.

In addition, participants were advised that the

University of the Pacific has no special program by which
it provides compensation for medical treatment if injury

f
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occurs during biomedical or behavioral research.
c.

Patient Population
One hundred sixty-four patients were found to have a

normal TBC, i.e., less than 200 mgjdL at the initial
screening (Visit #1).

This group will be referred to as

the "Normal Population".

Out of the remaining 77

participants, 20 persons did not meet the inclusion
criteria and therefore were excluded from subsequent
testing and follow up procedures.

This second group will

be referred to as the "Excluded Group".

The remaining

patients (N=57) were included in this study.

One month

after the initial cholesterol testing (Visit #2), six of
the included patients were unavailable for the follow up
testing.

Those patients were considered drop outs.

All

the participants on visit #2 successfully completed the
second follow up testing (Visit #3) and, therefore, the
total number in the "Drop Out Group" was six patients.

The

remaining 51 patients who completed the study from day one
to the end of the study period will be referred as the
"Study Group".
Data Collection
The following data were collected for the 241
participants during the initial screening:
1. Individual's name, sex, date of birth, weight,
height, and telephone number.
2. Name of participant's family physician.
3. Smoking status and number of cigarettes consumed
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per day.
4. Oral contraceptive use (females only).
5. High blood sugar.
6. Blood pressure.
7. Exercise level.
B. Family history of heart problems. e.g.,
Hypertension, angina, or heart attack.
9. Abnormal thyroid function.
10. Educational level.
11. Low fatjweight control diet.
12. Name and number of medications used on a chronic
basis.
13. Total number of risk factors (see list on page 73).
14. Initial total blood cholesterol level.
In addition, the following data were collected for the
51 participants who completed the study (the study group) :
1. Initial TBC level and the subsequent two follow up
levels.
2. Pre-test and post-test survey scores.
3. Patient's dietary andjor behavior modification in
visit #2 and #3 as a result of knowing his/her initial
TBC level.
4. Patient's attitude toward,the idea of blood
screening tests in community pharmacies.
5. Convenience and future utilization of such service
if it were to be available in their neighborhood
pharmacy.
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6. Indication of patients' willingness to pay for this
service and proposed fees.
7. Number of patients who had seen their physicians to
establish the final diagnosis.
8. Number of patients who actually received a
physician's order for lipid analysis as a result of the
pharmacist's referral service.
Participants were assured that any information that was
obtained in connection with this study that could be
identified with them would remain confidential and would be
disclosed only with their permission.
Selection of Instrument
The Boehringer-Mannheim analyzer (REFLOTRON) was used
to determine cholesterol levels of the participants in this
study.

All auxiliary instruments, devices, and supplies

were provided through Boehringer Mannheim Company.•

The

Reflotron analyzer was chosen because of the following
features:
1. It utilizes dry chemistry reagent tabs (no need
for blood dilution or centrifugation) .
2. It requires only 30 uL (about 2 drops) of whole
blood that can be obtained from a finger stick.
3.· It gives relatively accurate and reproducible
results (< 5% bias) in less than three minutes.
4. It requires minimal training and operating

"Boehringer Mannheim Diagnostics.
Indianapolis, IN 46250

9115 Hague Road.
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skills.
5. It can detect blood cholesterol levels in the
100-406 mgjdL range.
Reflotron Operation Procedures
Operating the Reflotron analyzer is simple and involves
the following three steps based on the manufacturer's
recommendation:
1. Turn on the power switch and wait for the analyzer
to warm up, the word 'READY' will be displayed.

Insert a

cholesterol calibration tab, which carries a programmed
magnetic code, into the Reflotron and close flap.

In a

moment, a 'CHOLESTEROL PROGRAM' message is displayed on the
LED screen.

Open flap and remove the programmed tab in its

original vial for next day use.

This calibration procedure

can be avoided by the use of individually prograruned
reagent tab which is slightly more expensive than the
uncoded tabs.
2. Remove reagent tab (the uncoded tabs were used in
this study for economic purposes) from vial and close vial.
Remove the protective foil.

Carefully draw blood sample

into capillary tube, avoiding air bubbles.

Dispense blood

sample (30 uL) onto center of red mesh area of tab using a
quick, smooth motion.

Do not allow pipette tip or

capillary tube to touch the tab.
3. Immediately insert tab with the reagent pad side up,
until a click can be heard.
the display, close the door.

When 'CLOSE DOOR' appears on
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Test name abbreviation 'CHOL' and countdown from 175
seconds to one will appear on the display.

When time is

up, test result will be displayed automatically, expressed
in mgjdL.

open door, remove tab.

All materials that came

in contact with blood, such as capillary tubes and lancets,
were discarded in a biohazard container.
Quality Control
A. CHECK TABS:

(Checking the optical system)

Each week, a check test is performed to check the
performance of the optical system of the Reflotron.

The

manufacturer's recommended test procedures are as follows:
1. Switch on the Reflotron.

Take a new check strip out

of vial and close vial immediately.
2. With no blood sample applied, insert the check strip
into the instrument and close flap.
3. The display 'CHECK' confirms that the coded data
have been correctly read into the instrument.

In about two

minutes, a set of three-digit values shows on the display.
4. Compare each of the three values with the
corresponding reference value (mean) displayed on the vial
label.

If the three values displayed are within the

specified confidence limits, the optical system is
functioning properly.
B. CONTROL SERA:

(Checking the entire system)

A universal sera (Precinorm U, Boehringer Mannheim
Diagnostics)

is used for checking the entire system. It

consist of a freeze-dried control that is reconstituted by
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dissolving the content of the vial in exactly two
milliliters of redistilled water.

Gently swirl vial for 30

minutes, do not shake vial to avoid the formation of foam.
1. Apply a control sera to a reagent tab using the
Reflotron Eppendorf pipette, which uses disposable tips and
insert the tab into the instrument.
2. Compare the values displayed to control sera range
printed on the package insert (usually 163-221 mgjdL) .

If

test value falls outside range, repeat test.
Control sera should be stored at 4°C after being
reconstituted.

A new vial is recommended to be used every

week.
Initial Blood Cholesterol Screening
During the initial total blood cholesterol (TBC) test
(Visit 1), each participant was asked to read and sign two
consent forms (Appendix A) before obtaining the blood
sample.

An alcohol swab was used to clean the

participant's finger and excess al.cohol was gently wiped
out using a 2X2 inch sterile pad.

Surgical gloves were

used during blood manipulation procedures to avoid direct
blood contact.
AUTOCLIXtm

A finger stick was performed using an

(Boehringer Mannheim Diagnostics) device that

utilizes a. sterile lancet. The first drop of the
participant's blood was discarded to ensure an
uncontaminated sample.

Thirty microliters of blood were

collected in a small capillary tube which is internally
coated with heparin lithium to guard aga.inst blood

I
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coagulation.

The drawn blood sample was then analyzed

using the standard testing procedures mentioned previously.
Within three minutes, participant's TBC result in mgjdL was
displayed on the screen.
During the three minute waiting period each participant
was asked to fill out a cholesterol data sheet (Appendix B)
which include personal data and a health questionnaire
intended to assess the patient's underlying CHD risk
factors.

Participants' exercise level was determined based

on a 4-point scale ranging from zero (non-active) to three
(active).

Educational background or the number of years

spent in learning was classified into five categories.
Participants with the highest educational level
(Postgraduate degree such as M.S. and Ph.D) were given a
value of 5, whereas participants with the minimal degree of
education (Grade School) were give a value of 1 (Appendix
B) •

Assessment of Risk Factors
In order to assess the number of CHD risk factors the
person might have, the following list of established risk
factors was used in this project:•
l.

Male Sex.

2.

Hypertension.

3.

Diabetes Mellitus.

4.

Use of oral contraceptives.

8

CHD risk factors selected from References 12, 13, and
37.

t
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5.

Severe obesity (> 30% overweight).

6.

Hypercholesterolemia (TBC > 200mgjdL).

7.

Family or personal history of heart attack

8.

Sedentary lifestyle (Physical inactivity).

9.

Cigarette smoking (10 or more cigarettes per
day)

10. Definite coronary heart disease, e.g., M.I.
subclassification of Screened Population
Subjects with an initial TBC of < 200 mgjdL were
assured that they had a normal level and were given
instructions to check their TBC in the next five years.
They were also advised to follow a good and balanced diet
and to maintain an ongoing exercise program.

All

participants were asked to fill out a pre-test survey which
assessed their knowledge and

1.~nderstanding

of high blood

cholesterol and the consequences of untreated high levels
(Appendix C).

Each participant went home with a nutrition

handout and brochures which provided up to date information
about maintaining a normal cholesterol level and good
dietary intake (Appendix D).

A specially designed

cholesterol screening wallet card was given to all
participants with their TBC result recorded and dated
(Appendix E) .
Subjects with an initial TBC of 200 mgjdL or higher,
who fulfilled the project's inclusion criteria, were
invited to participate in the study.

They were informed

that two follow up TBC tests during the next five months
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would be requested.

To be eligible for such follow up

testing, patients were asked to sign a preliminary
evaluation sheet (Appendix F) .

This signed evaluation

sheet provided the authority for the project investigator
to perform additional TBC testing, to refer patients to
their family physicians or suitable health care center.

In

addition, it gave the investigator the legality to receive
a copy of lipid analysis results performed at a standard
laboratory for follow up purposes.
Follow up Testing and Procedures
Between the period of the initial screening and the
first follow up test, patients with high TBC and additional
risk factors were contacted by phone.

This was intended to

motivate them to see their physician for further
evaluation.
On the first follow up test (Visit 2), TBC was checked
using the same testing procedures mentioned earlier.

Test

results were recorded in the patient's wallet card and any
TBC difference from the first visit was calculated for each
patient.

Patients who demonstrated a decline in

cholesterol level and those who did exercise and modified
their dietary intake of fats and cholesterol were
encouraged to continue doing so.

However, patients for

whom there was no improvement or slight increase in TBC
were advised to take a more active role in controlling
their TBC and to seek dietary council and medical
intervention.

Possible dietary changes and the value of

I!
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initiating exercise program was again reinforced.

This

visit was an excellent opportunity to answer patients'
questions concerning risk factors, dietary changes, TBC,
and coronary heart diseases.
At the time of the second follow up test (Visit 3), 51
patients had their TBC tested.

They were provided with a

list of eight blood tests available and were asked to
circle the number of test(s) they would use in the future
if these tests were to be available in their community
pharmacy (Appendix G).

They were also asked to answer a

post-test survey that includes five repeated pre-test
questions to assess any change in attitude and knowledge of
cholesterol and its association with heart disease
(Appendix H) , and to express their personal opinion and
attitude toward the idea of blood screening in community
pharmacies.

Finally, a certificate of participation was

awarded to all patients who completed the six month study
in recognition of their efforts to lower their TBC and to
reduce their chance of having coronary heart problems
(Appendix I) .
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Statistical Analysis"
several methods of statistical analysis, both
parametric and non-parametric, were used to detect the
significance of differences among means of the tested
parameters.

All statistical methods in this study were

applied at a probability level of less than 0.05.
In order to compare results of certain parameters, the
values obtained were coded first.

The study group

participants whose age was between 18-34 years of age were
coded a value of one, whereas those 34-60 years old were
coded a value of two.

Similarly, total blood cholesterol

(TBC) values were assigned a coded value of one (TBC of
100-199 mgjdL) and to a value of two (TBC of 200-400
mgjdL) .

The following is a list of the statistical

analysis methods used in this project:
1.

A one-way analysis of variance was used to

determine the difference between the means of TBC levels in
visit #1, #2, and #3 and used again to determine whether
there was a significant difference between the four
educational background levels.
2.

Scheffe's Post Hoc Test was used to compare

differences between the mean TBC levels for statistically
significant F-Test results.
3.

Student t-test was used to determine whether there

• All statistical analyses were performed on the Fortune
32:16 computer, using the Mini tab statistical program.
Fortune System Corporation, Belmont, California.
1982.
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was a significant difference between two groups when
applicable, while two sample t-test was used to compare the
difference between two sets of data containing unequal
patient numbers, e.g., the study group (N=51) versus the
normal group (N=164).
4. Two sample t-test was used to analyze coded data
such as age, education background, sex, exercise levels,
and difference in TBC results using the Reflotron analyzer
against those obtained via standard laboratories.
5.

The non-parametric Mann-Whitney test was used as an

alternative for the t-test for the difference between two
independent samples (number of risk factors in the study
group versus those of the normal population) assuming
samples were drawn from an unequally distributed
population.
6.

The correlation coefficient (r) was calculated for

13 different parameters to estimate the level of
correlation between examined parameters.
7.

Chi-square analysis was performed to compare sex

distribution between the study group against the normal
group.
Total blood cholesterol results of the three visits
along with pre-test, post-test results, and patients'
demographic data are presented in the results section.

RESULTS AND DISCUSSION
The relationship between elevated blood cholesterol and
increased risk of coronary heart disease (CHD) has been
well documented during the past 10 years.

There is now

solid evidence demonstrating that a 1% decline in serum
cholesterol results in a 2% reduction in risk of
CHD. 4 • 2 • 5 •32

The National Cholesterol Educational Program

(NCEP) was initiated in November 1985 to contribute to
lowering morbidity and mortality from CHD by lowering
cholesterol in those who are at risk.

The NCEP program's

main goal was to motivate all adult Americans to know their
cholesterol level by attending cholesterol screening
programs and to ask their physicians to have their
cholesterol tested.

However, less than half the adult

population (29-57%, Median 47%) have had their cholesterol
tested, according to the 1987 Behavior Risk Factor
Surveillance System from 33 states. 90

In addition, only 6%

of adults surveyed were able to provide a value for their
cholesterol level (range 1-19%).

This was attributed at

least in part to the problem of accessibility to and/or the
high cost for cholesterol test.
Now, with the availability of whole blood dry chemistry
analyzers, a non-expensive total blood cholesterol. (TBC)
test can be performed in less than five minutes in a nonfasting state.

Although the goal of dietary or drug

treatment is to lower LDL level, patients can be monitored
79
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on the basis of their TBC which serves as an indirect test
of LDL.

Measuring TBC has the advantage of low cost, the

use of non-fasting blood specimens involved in the
measurement, and the minimal amount of blood (two drops)
required.

A strong demand for establishing cholesterol

screening programs was addressed as an effort to encourage
more people to know their cholesterol level and what it
means.
This research project was conducted to investigate a
cholesterol screening and referral service in a community
pharmacy.

It was theorized that an easily accessible

community pharmacist could identify those patients at risk
of CHD through blood cholesterol measurement and from both
personal and family data.

This research project, in

contrast to any other published study, was also designed to
evaluate the impact of such proposed service on patient
outcomes in terms of blood cholesterol lowering during a
six month period, changes in behavior, referral to
physician and patient acceptance of the service.

The

project was not intended to evaluate its impact on
morbidity or mortality because of the limited study period.
The project's flow chart and time line is depicted in
Figure 4.
During the initial screening period (Visit #1}, a total
of 241 participants were screened for elevated total blood
cholesterol (TBC) in a non-fasting state.

It is important

to point out that the number of persons tested per day may

Initial
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- Non-fasting
-Adults (18-60 yrs.)
- Assess other
risk factors
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vary considerably between studies depending on several
factors.

These may include the number of screening sites

involved in each screening program, the nature and the goal
of such program, proposed or required fees for providing
such service, method of follow up if any, and the length of
the research study or screening program.
Ninety three participants out of the initial 241 stated
that they had their blood cholesterol checked (38.58%),
which is less than but close to the 1987 estimate of 47%
(29-57%).
During the initial screening, one hundred sixty four
participants were found to have a desirable blood
cholesterol level (< 200 mg/dL) regardless of their age or
sex.

Selected demographic and statistical data for this

"Normal Group" are presented in Table VII.

All

participants in this group were provided with general
dietary and risk factor educational material (Appendix D).
They were also advised to repeat their cholesterol
measurement within the next five years and to record their
levels in the cholesterol progress wallet card provided
(Appendix E) .
In contrast, 77 participants (31.95%) were found to
have TBC > 200 mgjdL who had not been told previously that
they had elevated cholesterol.

This might have been due to

the fact that their levels were considered to be normal
based upon the 1984 guidelines.

Surprisingly, 39 persons

(50.65%) out of these 77 person with moderate to high

!
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Table VII:
Selected Characteristics of Normal Population
(Total Blood Cholesterol < 200 mgjdL) •

Value

Parameter

164

Total Number Screened
Average TBc1 (Range)

163.8 ( 100-199)

Average Age (Range)

29.97 (19-63)

sex (Males:Females)

84:80

Family History of
Heart Problems (%)

83 (53.66 %)

Family History of
Heart Attack (%)

44 (26.83 %)

Average Number of
Risk Factors (Range)

1.35 (0-3)

1TBC= Total blood cholesterol.
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cholesterol levels had not had their cholesterol checked
(against a reported 25.57% that was estimated from pooled
results from 13,000 subjects).%

In another five day

screening study involving over 12,432 persons, it was
reported that approximately 50% of these people never had
their cholesterol level tested although 28% of them were
found to be at moderate to high risk for CHD.n
According to the pre-established inclusion criteria, 57
participants out of the 77 persons with TBC of 200 mgjdL or
over were accepted in the study (74.03%).

The remaining 20

participants (25.97%) were excluded from further blood
cholesterol testing and follow up procedures.

Selected

characteristics of these excluded persons are presented in
Table VIII.

One participant was excluded because she was

pregnant (first trimester).

It has been reported that

pregnancy could lead to false lipid results due to hormonal
and body fluid changes and she was advised that lipid
analysis be performed six to nine months after delivery.
Another two persons were 61 years old who had their TBC
checked before and were told that they had high levels,
therefore, were excluded.

The remaining 17 excluded

persons had their cholesterol checked previously and were
told that it was high, including one who stated that his
father, who is a practicing physician, would treat him.
The follow up procedure of this community pharmacy
screening project consisted of telephone contact within 2-4
weeks of Visit #1 (the initial screening) and written
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Table VIII:
Selected Characteristics of Excluded Patients.
rsc 2

FHx HP 3

FHx HA 4

4

203

YES

YES

4

CHK!TH 6

FEMALE

2

204

YES

NO

2

CHK/TH

27

MALE

3

202

YES

YES

4

CHK/TH

CT

29

FEMALE

1

200

NO

NO

4

PREGNANT

05

IG

61

FEMALE

2

224

YES

NO

3

CHK/AGE

06

MD

24

MALE

3

245

YES

NO

3

CHK/TH

07

KC

51

MALE

5

300

YES

NO

4

CHK/TH

08

GN

57

FEMALE

3

234

YES

NO

3

CHK/TH

09

JE

58

FEMALE

2

255

YES

YES

3

CHK/TH

10

MC

58

MALE

3

204

NO

NO

5

CHK/TH

11

sc

55

FEMALE

3

217

YES

YES

2

CHK/TH

12

GO

46

MALE

3

288

YES

YES

5

CHK/TH

13

CF

61

MALE

4

217

YES

NO

2

CHK/AGE

14

SF

35

MALE

3

233

NO

NO

4

CHK/TH

15

cc

59

MALE

3

239

YES

YES

5

CHK/TH

16

RK

43

HALE

3

270

YES

NO

5

CHK/TH

17

OS

46

MALE

3

267

YES

YES

5

CHK/TH

18

HN

46

FEMALE

2

256

YES

NO

1

CHK/TH

19

HI

55

FEMALE

2

234

YES

NO

5

CHK/TH

20

RM

29

FEMALE

3

233

YES

NO

4

CHK/TH

#

Code

Age

01

RG

36

MALE

02

cs

44

03

BT

04

Sex

# RF l

1Number of ~isk factors.
3Family history of heart problems.
5educational background.

Ed Bg 5 Reasons for
Exclusion

2Total blood cholesterol.
4 Family history of heart attack.
6 checked before and told high.
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communication between Visit #1 (first follow up) and Visit
#3 (the end of study period).

The purpose of such

communication was to remind the participant to adhere to a
healthy diet and to maintain their regular exercise level,
especially those with high TBC level andjor those at high
risk of CHD.

one month after the initial screening (Visit

#2 or the first follow up test), six patients (10.53%) out
of the 57 accepted participants were unable to attend this
first follow up test and thus were placed in the "Drop out
Group".
group.

Table IX gives selected characteristics of this
With the exception of one patient, all drop out

patients left the state and therefore were unavailable for
follow up (83.33%).

Patient #5 showed no interest in the

follow up testing and stated that she would see her
physician to have a lipid analysis performed.
The remaining 51 patients, The study Group,
successfully continued the second follow up test (Visit #3)
with no drop outs in spite of the two month gap between the
two visits #2 and #3.

This was thought as an initial

indicator of the study group's interest and
conscientiousness in knowing what might be the effect of
dietary and/or behavior changes on their blood cholesterol
levels.

It is worth analyzing, at this point, the behavior

of the study group in terms of their attending the second
follow up with no drop out.

It is possible to assume that

these participants became more concerned and aware about
their high cholesterol levels and therefore were willing to
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Table IX:
Selected Characteristics of Drop-Out Patients.

sex

# RF 1

TBC 2 FHx HP 3 FHx HA 4 Ed Bg 5 Reasons for
drop out

#

Code

Age

01

MM

19

Male

2

254

NO

NO

3

NAFF 6

02

cc

24

Female

2

286

Yes

Yes

3

NAFF

03

SG

22

Male

3

209

Yes

Yes

3

NAFF

04

RM

45

Female

4

216

Yes

NO

4

NAFF

05

BP

35

Female

3

212

Yes

Yes

3

No interest

06

AN

34

Male

3

203

Yes

No

4

NAFF

lNumber of risk factors.
2Total blood cholesterol.
3 Family history of heart problems.
4 Family history of heart attack.
5Educational background.
6Not available for follow up visits.
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have more tests, in spite of the possible physical
discomfort or inconvenience.

It might also be a subjective

measure of satisfaction with the project, because they
could have chosen to not appear for the second test with no
obligation.

The comprehensive demographic and statistical

data of the study group (51 patients) including their TBC
on the three visits, personal and risk factors assessment
data are presented in Tables X and XI.
Table XII summarizes major descriptive statistical data
for the study Group (N=51), the Normal Group (N=l64), and
the Total Population Group (N=241).

Since the study group

patients were included in the overall total population, all
performed statistical analysis were based upon the
difference between this group and the normal population
group only, unless otherwise indicated.
General Comparative Analyses
The mean total blood cholesterol of the normal group
was found to be 163.80 mgjdL which, because of the
inclusion criteria, is significantly lower than that of the
study group at 225.69 mg/dL (P < 0.001).

A histogram

presenting the TBC distribution of the three groups is
presented in Figure 5.

As can be seen, the TBC

distribution of the total population exhibits a bell-shaped
curve which is a characteristic feature observed in most
clinical and epidemiological studies including the
Framingham study.

The study group represents the right

half of the curve with TBC of 200 mgjdL and above, while
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Table x:
study Group comprehensive Data.

TBCI'

230
235
222
289

228
210
219
221
216
252
210
23~

202
251
246
208
207
223
20~

223
216
231
200
2~1

238
210
256
242
206
21~

217
20~

225
227
222
229
257
21~

21~

284
201
213
201
239
209
21~

300
208
212
202
232

TBC2'

rsc3•

17~

182

237
235
285
217
193

22~

227

229
177
227
139
196
202
221
131
213
172
232
203
197
209
168
176
231
171
169
198
190
197
196
201
217
196
236
211
216
227
229
203
236
F9
~~

198
225
193
215
235
174
197
173
157

211
273
216
ISS

237
181
181
219
210
189
211
266
199
247
206
215
204
208
16~

180
23<4
214
240
157
194
229
199
185
192
20~

225
230
146
243
236
216
157
281
199
184
180
220
179
215
225
191
201

\ Change' \ Change•

23.9130
-0.8511

~0.8696

4.6809

-5.85~9

~.9ssc;

1 .38~1
4.8246
a. o9s2
-3.6530
-3.6199
18.0556
9.9206

5.5363
5.2632
7 .!429
-8.2192
18.0995
16.2037
13.0952
o.oooo

5.2381

16.5957
o.oooo
11.9522
22.3577
-2.4038
16.9082
-4.0359
0.4902
11 '6592
3.2407
27.2727
12o0000
4. 149~
28.1513
19.5238
22.6563
21.4876
4.3689
8.~112

7.3733
-6.3725
12.8889
-3.9648
4.9550
5.6769
II ,6732
-7.0093
s. 1402
16.9014
10.9453
13.6150
1.4925
5.8577
7.6555
o.oooo
21.6667
16.3462
7.075~

~~

14.35~

178

32.3276

19.57~~

-4.4554
-5' 9761
19.1057
·18.7500
0.4831
3.587~

o.oooo
6.7265
2~.0741

22.0779
·17.0000
I 1.2033
-0.8403
25.2381
24.2188
5.3719
3.3981
13.5514
, , 5207
o.oooo
o.oooo
-1.3216
34.2342
-6.1 13~
8.1712
-0.93~6

. 26.6355
1.0563
0.9950
13.61~0

10.4478
7.9498
14.3541
o.oooo
25.0000
8.1731
5.1887
3.4653
23.2759

.\ge

Sex'

21
45
39
40
27
22
52
28
20

1
1
1
0
1
0
0
1
0
1
0

4~

52
22
60
48
38
46
23
24
60
27
26
2~

23
22
22
22
24
28
27
46
58
22
23
54
29
52
so
21
23
56
29
46
48
45
40
43
31
52
~5

53
21

I

0
I
I

1
0
0
I
0
0

1
0
0
0
0
0
0
I

0
0
I
0
0
I

0
0
0
I

0
1
I

0
1
1
0
1
I

0
0
0

"Total blood cholesterol, Initial screening (Visit # 1)
borotal blood cholesterol, Visit # 2
<Total blood cholesterol, Visit # 3
d% Change = (a - b) X 100
e% Change = (a
c) X 100
11 = Male ; 0 = Female

-

I
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Table X:
study Group comprehensive Data. {Continued)
Ed- Bg<

Ex-Lv•

3
5
4
3
4
3
3
3

2
0
1
0
I
0
I
I

2

3
4

5
3
2
3
3

I
3
2

2
1
2

I

s
3
3

5

2
0
3
3
I
3

4

2

3

~

3
I
2
I
2
2
I
3
I
2
I
3
I
2
2
I
0
0
3
I
2
2
2
2
3
I
0
2
I
2
3

~

2 .

5
4
3

3
4
3
3
3
3
2
3
3
5
3
3
4
4

3
2
3
3

s
3
5
5

'

3
3
4
2
4
3
3

8

3
5
3

2

3

5

I RfC Pre-- t•

4

~

2
2

3
I
2
2
1

3
4
2
.2
2
3
3
3
3
I
3
3
3
2
3
2
I
3
3
2
2
3
I
I
4

10
10
10
10
10
10
10
10
10
10
8
I0
B
10
10
I0
10
8
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
I0
8
10
10
10
6
10
10
10
10
10
10
I0

Post-t• VI-V2' 1'1-Vl• 1'2-Vl'

10
10
10
10
10
10
10
10
10
10
10
10
10
I0
10
10
10
10
10
10
I0
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

55

~8

-2
·13
4
II
17

11
II
IS
12

-a

-B
39

25
II
39

0
30
55
-5
35
·9

1
26

7
63
24
10
S7
41
58
52
9
18
16
-13
29
-9

,

13
30
-15
II
48
22
29
3
14
16
0

65
34
IS
29
75

IS

·IB
40
35
33
0
46
-9

-IS
47
-39
I
8
0
15
52
51
-3~

27
-2
53
62
13
7
29
25
0
0
-3
76
-14
21
·2
57
3
2
29
21
19
30
0
75
17
II
7
54

·7
13
24
12
I
·2
-I 0
48
·4
B
·I I
7
-9
-45
·B
-34
-34
17
-I
-I I
~~

-12
·58
17
-69
12
~

-39
-2
'I
9
13
-29
6
65
-27
·9
13
46
-45

-20
0
IS
~

14
0
10
-17
-4

-22
-21

Educational background.
bExercise level.
<Number of risk factors.
dPre-test score.
"Post-test score.
1
Total blood cholesterol difference (visit 1 - visit 2) •
9 Total blood cholesterol difference (visit 1 - visit 3) •
hTotal blood cholesterol difference (visit 2 - visit 3) •

91

Table XI:
Study Group Descriptive Statistics.

N

Mean

Median

STOEVg

SEMEANh

Min

Max

TBC1 8

51

225.69

221.00

22.47

3.15

200

300

TBC2b

51

204.61

201.00

24.73

3.64

157

285

TBC3c

51

207.20

206.00

28.48

3.99

146

281

% Changed

51

9.04

7.66

9. 76

1.37

·7.01

32.33

% Changee

51

7.94

5.37

11.34

1.59

·18.75

34.23

Age

51

36.43

31.00

13.37

1.87

20

60

Education
background 51

3.51

3.00

0.93

0.13

2.0

5.0

Exercise
level

51

1.57

2.00

0.96

0.14

0.0

3.0

# R.Fsf

51

2.61

3.00

1. 0

6.0

score

51

09.77

10.00

0.76

0. 11

6.0

10.0

Post-test
score

51

10.00

10.00

0.00

0.00

10.0

10.0

1. 10

0.15

Pre-test

aTotal blood cholesterol, Visit # 1.
bTotal blood cholesterol, Visit # 2.
cTotal blood cholesterol, Visit # 3.
d% Change = (a - b) X 100.
e% Change = (a - c) X 100.
fNumber of risk factors.
gstandard Deviation.
hstandard Error of the Mean.
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Table XII:
comparison of Selected Descriptive Statistics of the
Study, Normal, and Total Population Groups.

N

STUDY:

51

M: F 1
Rat 1 o

164

1 . TBC
2. Age
3. R. F.

Ml N

MAX

225.69 221.00 22.47
3 6. 4 3 31 . 00 13.3 7
2. 61
3. 0 0 1 . 1 0

3 . 15
1 . 64
0 . 15

200
20
1

300
60
6

163.80 167.00 23.30
29.97
25.00 9.46
1•35
1 . 0 0 0.80

1 • 82
0.74
0.06

100
19
0

199
63
3

184.34 181.00 38.78
32.66 28.00 11 . 6 2
2. 00
1 . 77
1. 0 7

2.50
0. 75
0.07

100
19
0

300
63
6

84:80

1 • TBC
2. Age
3. R. F.
Population 241

MEDIAN STDEV 2 SEMEAN 3

22:29

1. TBC 4
2. Age
3. R. F. 5
NorMal:

MEAN

120:121

lsex distribution, Males:Females.
2standard Deviation.
3 standard Error of the mean.
4Total blood cholesterol.
5Number of risk factors.
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left portion represents people with normal TBC of <200
mg/dL.
As can be seen from Table XII, the study group patients
tend to be significantly older compared to the normal group
(means 36.43 and 29.97 years, respectively, P< 0.05).

The

median was found to be 31 for the study group, 25 for the
normal group, and 28 for the total population.

Examining

Figure 6, it was decided to use 35 as the breakpoint to
classify the study group into two subgroups, those.who are
under the age of 35 and the older patients whose age is 3560 years old.
The sex distribution in the three groups tends to be
equal, although more females were found in the study and
total population groups than males (F:M ratio is 29:22 and
121:120 respectively).

The normal population had less

females than males (80:84) compared to the study group
(29:22), although this difference is not statistically
significant (calculated chi-square value =1.014, P> 0.05).
This is a unique finding in this study because most
clinical and epidemiological studies reported that coronary
heart disease tends to occur 4-5 times more in males than
in females.

In fact, male sex, according the NCEP expert

panel of 1987 and the Framingham study, is considered a
risk factor for CHD.
When comparing the study group risk factors to those of
the normal population, it was found that study group
patients had a statistically significant higher risk for
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CHD than those of the normal group (mean of 2.61 versus
1.35, P< 0.01).

Since there is a possible argument that

the study group may not represent an equally distributed
sample, a non-parametric analysis was performed using the
Mann-Whitney U test which is a non-parametric alternative
to the two sample t-test.

The non-parametric analysis of

the number of risk factors between study and normal groups
was also found to be statistically significant (P< 0.01).
To assess the potential effect of the other risk factors,
elevated TBC was temporarily excluded as a risk factor in
the study group and statistical analysis was then
perfoL~ed.

The difference between the study and the normal

group was found to be no longer statistically significant
(mean 1.61 versus 1.36 respectively, P= 0.12).

This might

confirm the association between elevated blood cholesterol
as an independent factor for CHD.

Table XIII summarizes

statistical analysis results comparing the study group data
against those data reported for the normal population
group.
Study Group Comprehensive Analysis
The results reported in Table XI shows the mean
reduction of TBC during the follow up visits (Visit 2 & 3).
The maximum and minimum TBC levels were lowered from 200300 mgjdL initially at visit 1 to 157-286 mgjdL in visit 2
a.nd were lowered further at the end of study period, with
visit 3 down to 146-281 mgjdL.

This represents a percent

change of -7.01 to 32.33% (-15 to 75 mgjdL) in visit 2 and
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Table XIII:
Statistical Comparison of the Study Group
Versus the Normal Population Group.

Parameter

N

Mean

T Value

P Value

TBC1
-study
-Normal

51
164

225.7
163.8

17.03

P< 0.01

Age (years)
-study
-Normal

51
164

36.40
29.97

3.21

P< 0.01

sex2
-Study
-Normal

51
164

Number of
Risk Factors
-study
-Normal

51
164

2.61
1. 35

Number of
Risk Factors
Excluding TBC
-Study
-Normal

51
164

1.61
1.35

x2=

1 Total blood cholesterol, mgjdL.
2Based on Chi-Square statistics.

1. 01

P> 0.05

7.61

P< 0.01

1.57

P= 0.12
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and a -18.75 to 34.23% (-39 to 76 mgjdL) in visit 3.

Forty

four patients (86.27%) in visit 2 and 35 patients in visit
3 of the study group stated that they changed their diet
and/or improved their exercise as a result of the
pharmacist's initial screening.

Furthermore, 25 patients

in visit 2 (49.02 %) and 22 patients in visit 3 (43.14%)
showed a lowering in TBC level below the desirable 200
mg/dL cutoff point.

In addition, 40 patients (78.43%) in

visit 2 and 37 patients (72.55%) in visit 3 demonstrated a
lowering in TBC below their baseline levels in visit 1
(Table X and Figure 7).

On the other hand, only eight

patients (15.69%) in visit 2 and nine patients (17.65%) in
visit 3 had an increase in their TBC levels.

It has been

suggested that an expected 30-40 mgjdL reduction in TBC can
be achieved over time by switching from the typical
American diet to the step-one diet.

An additional 15 mg/dL

could be achieved by adhering to cholesterol-lowering diet
as the patient advances to the step-two diet. 20
The One-Way Analysis of Variance of the TBC on these
three visits showed a statistically significant difference
among the three groups, P< 0.01 (Table XIV).

The Scheffe's

test result showed a highly significant difference in mean
TBC between visit 1 and 2 and between visit 1 and 3, P<
0.01.

In contrast, no significant difference was found

between mean TBC levels in visit 2 and 3, P> 0.05.

This

indicates that patients in the study group were able to
lower their mean TBC within a one month period and
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Table XIV:
One-Way Analysis of Variance of Total
Blood Cholesterol in the Three Visits.a

Mean total Blood Cholesterol
F
Ratio
( mg/dL )
Visit 1

225.69

Visit 2

204.61

Visit 3

207.20

ascheffe Value:

10.49

p

Value

<0.01

Significant difference between visit
1 and 2 and between Visit 1 and 3,
(P< 0.01). No significant difference
between visit 2 and 3, (P> 0.05).
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succeeded in keeping it at a significantly lower level
compared to their mean initial cholesterol level.
Additionally, this might emphasize the need for early
follow up procedures to assure patient compliance with
prescribed diet or drug treatment especially for long-term
management of elevated blood cholesterol.
Six patients on the first follow up test (visit 2),
four at high risk and two at moderate risk of CHD, reported
that they contacted their physician as a result of the
initial screening to establish their diagnosis.

In

addition, two more patients at high risk and another
patient at moderate risk reported that they had seen their
physician during the time interval between visit 2 and
visit 3.

It is important to note here that standard

laboratory lipid analyses had been ordered for these nine
patients by their physicians.

Table XV shows that

hypercholesterolemia was confirmed in all patients (N=9)
referred with the exception of one patient who successfully
lowered her TBC below 200 mg/dL.

This patient had reported

standard laboratory TBC result of 181 mg/dL on April
25,1988, v:hich was found to be 177 mgjdL in May 4, 1988
using the project analyzer "Reflotron".
There was a "very good" association between standard
laboratory results compared to that performed in the
community pharmacy project.

The difference in both TBC

reported (Table XV) in those nine patients was not
statistically different from the results reported fort the

I

102

Table XV:
Comparison of Two Reflotron Results Against
Those Obtained at standard Laboratories.a
study Results
codes Confirmed

Reflotron

TBCb (md/dL)

Test date

Standard Labs.

TBC (mg/dl)

Test date

04

Yes

289 ; 285

03!23; 05/02

252

04/03/88

08

Yes

221 ; 229

03/23;06/02

235

06/21/88

09

Yes

216 ; 177

03/29;05/04

181

04/25/88

10

Yes

252 ; 227

03/30;05/03

251

04/20/88

24

Yes

241 ; 231

04/08;05/10

214

06/16/88

36

Yes

229 ; 216

04/18;05!19

272'

04/25/88

37

Yes

257 ; 227

04/18;05/19

277'

04/20/88

40

Yes

284 ; 236

04/19;05/25

277

04/26/88

47

Yes

300 ; 235

04/25;06/17

275

06/03/88

189
168
177
223
240

04!12/88
07/01/88
02/11/87
12/15/87
09/16/88

Additional Out of the Study Comparison Data:d

Volunteer

Number:

1
2
3
4
5

188
178
160
217
230

04/12/88
07/01/88
04/21/88
04/15/88
09!16/88

I

aNo statistical significant difference (P= 0.69
and P= o . 21) .
bTBC= Total blood cholesterol.
cDelta Medical Laboratory.
dNo statistical significant difference (P= 0.81).

r
r

!-
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same nine patients by standard laboratories (means 254.3
versus 248.2 mg/dL, P= 0.69 for TBC initial levels and
229.2 versus 248.2, P= 0.21 during visit 2 and 3).
Additionally, a group of five volunteers who had their
total blood cholesterol measured at standard laboratories
were tested in this community pharmacy project to compare
the laboratories' results to that of the Reflotron.

Again,

the difference between these project's results and those of
standard laboratories were found statistically
insignificant (study group mean of 194.6 versus 199.4 for
the standard laboratories, P= 0.81).

This was found to be

in accord with the reported accuracy and precision of the
Reflotron analyzer. 76 •77 •80 • 81

On the other hand, the presence

of inter-laboratory variation in TBC measurement was
confined to only one laboratory.

This laboratory reported

relatively high values compared to those obtained during
the community pharmacy screening tests (patient #36 & #37
in Table XV).

This problem of variation of serum

cholesterol determination from one laboratory to another
has been addressed in the literature. 76 •79

For this reason

the National Committee for Clinical Laboratory Standards
(NCCLS) through its council has approved the National
Bureau of Standards (NBS) definitive method and the center
for Disease Control (CDC) reference method and their
certified reference materials as the accuracy base for
serum cholesterol measurement in the United states.

The

CDC in a special repore6 stated that "The utilization of
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the National Reference system for cholesterol will assist
the organized national effort to assure and monitor
reliable cholesterol determination in the laboratories."
Therefore, users need to know the limitation and the
percent bias of the new simple-to-operate desk-top
analyzers before adopting them for routine patient use.
Data on the patients' educational background (which
reflects the number of years of education) were collected
to investigate its effect on patients' initial TBC and
subsequent behavior changes and their effect on the final
cholesterol levels.

Educational background was assessed

using a scale from 1 (Grade School) to 5 (Postgraduate
degree) as can be seen in Appendix B.

None of the study

group patients had an educational background below high
school level (level 2).

The average educational background

level of the study group was 3.51 (range 2-5), an education
above the undergraduate level.

Therefore, they would be

expected to have a relatively high pre-test score and even
higher post-score results.

As expected, the pre-test score

ranges from 60-100% while all post-score test were at 100%,
a statistically significant difference at P< 0.05.
To evaluate the influence of the number of years of
education on final blood cholesterol, a One-Way Analysis of
Variance was performed to compare TBC of the four
educational levels in visit 2 and 3 to that at visit #1
(initial screening test).

As shown in Table XVI, the

calculated F-values were 0.41, 0.98, and 1.34 for visit 1,
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2, and 3 respectively, whereas F-table value was found to
be 2.8.

It is concluded that there was no statistically

significant difference in terms of TBC changes during the
three visits between the investigated four educational
background levels.

It is worth noting that patients in the

four educational levels had successfully lowered their mean
TBC levels in visit 2 and 3 compared to their initial mean
levels.

However, patients with high school level and the

postgraduate degree patients did worse in visit 3 compared
to visit 2, though still less than their initial mean
levels.
Investigating the role of sex in lowering TBC, a two
sample t-test was performed comparing male versus female
mean TBC levels at the three visits.

It was found that

there were no significant differences in mean TBC levels
between males and females in visit 1, 2, or 3 (calculated
T-values are 0.12, 0.21, 1.41 respectively; T-table 50,
a1pha=0.05 is 1.65).

Mean total blood cholesterol (TBC) of

males decreased from 226.3 in visit 1 to 205.0 in visit 2
and even lower at 201.0 at the end of the study period
(visit 3) .

On the other hand, mean TBC of females

decreased from 225.5 mg/dL in visit 1 to 203.6 in visit 2,
but increased again to 212.2 mgjdL in visit 3.

It is

documented that as people get older their TBC tends to
increase to a certain degree.

Therefore, we investigated

the effect of age on TBC by assigning all study group
patients 35 years of age and under to subgroup 1 and those

106

Table XVI:
One-Way Analysis of Variance of Effect of
Educational Background on Blood Cholesterol.

Education Background Levela

F

p

Variable
level2

level3

level4

levelS Ratio Value

Visit 1

232.60

223.36

223.55

230.40 0.41

Nsb

Visit 2

196. 2 0

200.88

207.91

214.50 0.98

NS

Visit 3

213.00

201.32

204.73

221.70 1. 34

NS

aLevels 2, 3, 4, and 5 represent high school,
undergraduate student, undergraduate degree,
and postgraduate degree classes respectively.
bNs

=

Non-Significant difference.
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of 36-60 years old to subgroup 2.

The study patients were

also categorized to two subgroups based on their TBC by
coding their TBC into either subgroup l=TBC of 100-199
mg/dL and subgroup 2=TBC of 200-300 mgjdL.

Using this

coding system for TBC and age, there was no statistically
significant difference between younger patients (<35 years
old) and older patients (36-60 years old) in terms of TBC
in visit 1 (mean of 224.8 and 226.6 mgjdL respectively, P=
0.78).

In contrast younger patients did significantly

better in terms of lowering their initial TBC than older
patients in visit #2 and maintained this difference to the
end of the study period (means 197.1 Vs. 212.4, P= 0.025 in
visit 2, and 197.5 Vs. 217.3 in visit 3).

When the

difference in mean TBC between (Visit 1 - Visit 2) and
(visit 1 - visit 3) was compared in terms of age code,
younger patients had significantly higher mean TBC
differences in visit 2 and 3 compared to visit 1 (mean
lower TBC is 27.7 Vs. 14.2 mgjdL between visit 1 and visit
2, P< 0.05 and 27.3 Vs. 9.3 mgjdL between visit 1 and 3, P<
0.05.

This might indicate that younger people are

relatively easier to motivate to lower their TBC and to
change their lifestyle than older people.

If this was

assumed to be the case 1 it seems prudent to start screening
adult individuals 20 years and older or perhaps earlier in
the presence of strong family history of CHD.

Early

detection and management of elevated TBC and assessment of
underlying risk factors may be of potential value in
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halting or even reversing the process of fatty streak build
up and the development of atherosclerosis and CHD.
A correlation matrix of TBC for the three visits,
difference and percent changes in TBC during these visits,
study group age, education level, exercise level, number of
risk factors, pre- and post-test scores, was performed.
There was no strong correlation between any of these
parameters (r > 0.90 or higher).

However, several positive

correlations were found between TBC in visit 1 and that of
visit 2 and 3 and between visit 2 and 3 (r= .515, 0.510,
and 0.537, respectively).

In addition, positive

correlations were found between age and TBC in visit 2 and
3 (r= 0.29 and 0.36), number of risk factors and TBC in
visit 1, 2, and 3 (r= 0.37, 0.32, and 0.26).

On the other

hand, exercise level of the study group patients was
negatively correlated with TBC in the three visits,
although the correlation was weak (r= -0.436, -0.451, and
-0.316). It is important to note that although TBC and
hypertension, for example, are both independent and strong
predictor risk factors of CHD, their correlation
coefficient was reported to be 0.12 indicating weak
correlation. 10 • 13 • 67

Nevertheless, it was found in the same

Framingham study that the increase in blood pressure
paralleled the increase in total blood cholesterol.

Thus,

in hypertensive individuals, blood cholesterol related to
CHD risk was found to be strong and graded from level 182
mg/dL and higher and not restricted to the 75th and 90th

I

I
I
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percentile. 9 •~

Furthermore, it should be remembered that

CHD is a multifactorial health problem and not a disease of
a single etiology.

No one risk factor for CHD is a

rigorous determinant by itself because the risk associated
with any single factor varies with the constellation of
other existing factors.

Accordingly, multiple intervention

should be targeted to lower elevated blood cholesterol and
blood pressure, decrease the number of cigarettes smoked,
and control elevated blood sugar.

Also, lowering fat and

cholesterol consumption and maintaining ideal body weight,
screening for secondary hyperlipidemia including
medications that might affect blood cholesterol or blood
pressure, and other outlined lifestyle modification all
contribute to lowering the incidence of CHD morbidity and
ultimate mortality.
Table XVII lists the study group patients on chronic
medication, the number of drugs and their therapeutic
categories used per patient.

Thirteen patients (25.49%) of

the study group use medications on a chronic basis (mean
usage of 1.85 drugsjperson).

As expected, approximately

85% of these patients are above the age of 40 years.

In

the 20 year old patient (#9), rheumatoid arthritis was
incorrectly diagnosed and the patient reported at the end
of the study period that she was no longer taking her
medication in light of the new diagnosis.

The other 23

.year old patient is taking minocycline for treating acne,
in addition to her birth control pills, indicating no
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Table XVII:
Study Group Patients on Chronic Medications.

# of
Meds

Age TBC1a

TBC2

TBC3

04

40

289

285

273

3

DiabetajLasixj
Synthroid

07

52

219

227

237

2

PremarinjSynthroid

09

20

216

177

181

1

Clinoril

11

52

210

199

210

2

Premarin/Provera

13

60

202

202

211

2

SeldanejProvera

17

23

207

172

206

2

Minocycline;scpb

19

60

204

203

204

1

Atarax

31

58

217

201

192

2

EstrogenjSynthroid

36

52

229

216

243

2

ModureticjPremarin

37

60

258

227

236

4

L-ThyroidjPremarin/
Inderal and Dyazide

40

56

284

236

281

1

Estrogen

46

43

215

215

215

1

synthroid

49

45

12

197

201

1

Estrogen Patch

aTBC
bBcP

=

Code

=

Total blood cholesterol.
Birth control pills.

List of Drugs
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underlying severe disease condition.

The effects of

medications used by the rest of eleven patients on blood
cholesterol level were explained on an individual basis and
patients were advised to communicate the information with
their physician.

i

[-
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Attitude Toward the Feasibility and Future
Implementation of Blood Screening in Community Pharmacies
During the final cholesterol test (visit 3) all
patients were asked to complete a questionnaire by circling
the appropriate answer indicating agreement or disagreement
with the statements.

The subject's willingness to pay a

reasonable fee for this service if it were available in
their community pharmacy was also investigated.

Suggested

fee levels were provided to each patient, namely, $3 or
less, $5, $10, and more than $10 (See questions 11-14,
Appendix G).

Ninety eight percent (50 of 51) of the 51

study patients stated that they strongly liked the idea of
screening blood cholesterol in community pharmacies.
person showed moderate acceptance of this idea.

One

All study

group subjects agreed that providing this proposed
community service would be very convenient for them.

Forty

seven patients (92.16%) showed a willingness to pay for
this service if it were available in a community pharmacy.
Only four patients (7.84%) reported they were unwilling to
pay for this service.

When asked about the reason for not

paying for the services, some stated that unless they have
medical problems, or had a strong family or personal
history of CHD, they would not have their blood level
tested.

In others, they suggested that University of the

Pacific should pay for this service during the initial
student enrollment or as an ongoing service as a part of
the University Health Center services.

For those who

r

c
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showed a willingness to pay, an average of $4.55 was
proposed as a reasonable fee to charge for this service
(Range $3 to $10).

Keeping in mind that this project was

conducted in an academic environment, where most of
project's participants are students, most participants
circled $3 or less.

Further, since this was an

experimental service not covered by conventional health
insurance, many would be reluctant to endorse it as a high
cost service.

However, with more widespread and effective

marketing of this service, it may be financially feasible
to provide it at low cost to the public.
When subjects were asked to identify which of the eight
available tests they would use in the future, cholesterol
(98.0%) and triglycerides (62.7%) were the two most
desirable tests.

This might be the result of intensive

media coverage of the CHD/cholesterol issue during the
period of this research project.

In fact, April 1988 was

chosen as the "Know Your Cholesterol" month in an effort to
motivate everyone to know hisjher cholesterol level.

Table

XVIII reports the number and percentage of patients who
indicated interest in future utilization of blood tests if
available.

In a five-week study~, 443 subjects completed

a pharmacy blood service questionnaire involving blood
level list of nine blood tests.

Cholesterol and potassium

were reported to be the tests subjects showed most interest
in their availability in a community pharmacy (72.7% and
70.01% respectively), while triglycerides came fifth next

--------
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Table XVIII:
Subjects Interest in Future Blood
Level Measurement in Community Pharmacy.

Tests

Available

Number
of
Subjects

%

Cholesterol

50

98.0

Triglycerides

32

62.7

Hemoglobin

16

31.4

Glucose

24

47.1

Uric Acid

12

23.5

Serum creatinine

16

31.4

Blood Urea Nitrogen

12

54.9

Liver Function Tests
(GGT, SGOT, SGPT)

19

37.3

f
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to glucose and hemoglobin (49.9%).
Table XIX shows the number of patients in the study
group whose TBC increased during visit 2 and 3, and
corresponding behavior changes.

Nine out of the listed 13

patients in visit 2, and 12 of the 13 patients in visit 3
showed a matching result that corresponds to their behavior
change.
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Table XIX:
Behavior Changes Versus Increased Cholesterol
at Visit 2 and Visit 3.

Code 8 Age

Visit

Visit

Visit

1

2

3

Diet/Exercise
Changes

Did rscb
Decreased?

v2<

v3d

V2

V3

02

45

235

237

224

NO

YES

NO

YES

03

40

222

235

211

YES

YES

NO

YES

07

52

219

227

237

NO

NO

NO

NO

13

60

202

202

221

NO

NO

YES

NO

14

48

251

221

266

YES

NO

YES

NO

16

46

208

213

247

YES

YES

NO

NO

18

24

223

232

215

YES

YES

NO

YES

23

23

200

176

234

YES

NO

YES

NO

25

22 I . 238

171

240

YES

NO

YES

NO

32

22

204

217

204

NO

YES

NO

YES

34

54

227

236

230

NO

NO

NO

NO

36

52

229

216

243

YES

NO

YES

NO

38

21

214

229

216

NO

NO

NO

NO

acode number of patients in the study group
whose cholesterol increased during Visit 2
and Visit 3.
bTotal blood cholesterol.
cvisit 2.
dvisit 3.

SUMMARY AND CONCLUSION
This research project was undertaken to investigate the
feasibility of conducting a cholesterol screening program
in a community pharmacy.

It was targeted toward

identifying individuals with high blood cholesterol levels
and those at high risk of coronary heart disease (CHD).
Since CHD is usually a silent and slowly progressive
disease that presents no early clinical symptoms, it was
theorized that early detection of those at risk could
advance the time of their diagnosis and hence enhance their
prognostic value.

Early detection and management of

patients with hypercholesterolemia and those at CHD risk
through screening programs would help eliminate or control
these risk factors by taking preventive measures early
before progression of the disease.
In the 51 patients of the study group, there was a
statistically significant reduction in mean total blood
cholesterol (TBC) levels in visit 2 and 3 compared with the
initial mean level (P< 0.01).

The mean percent changes in

TBC between visit 1 and 2 was 9.04% (range -7.01 to 32.33%)
and 7.94% (range -18.75 to 34.23%) between visit 1 and 3.
Furthermore, 25 patients (49.02%) in visit 2 and 22
patients (43.14%) in visit 3 had successfully reduced their
TBC to the recommended level (less than 200 mgjdL).
Compared with the mean baseline TBC level, 41 patients
(81.39%) and 37 patients (72.55%) had a decline in TBC in
117
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visit 2 and visit 3, respectively.

The study group

patients were found to have a significantly higher number
of risk factors compared to those of normal population
group, P< 0.01.

The drop out rate was found to be 10.53%

(six patients) throughout the six month study period (as
compared with a drop out rate of 27.7% after two months in
a multi-site screening program) . 94

No age, sex, or

educational background differences in terms of mean TBC
levels were found during the initial TBC testing.

However,

young patients (less than 35 years old) significantly
lowered their mean TBC levels compared with older patients
(35-60 years old), P< 0.05).

No difference in mean TBC was

found between male and female patients in visit 2 or 3
although both males and females were able to lower their
mean TBC levels in these two visits.

Similarly, there was

no significant difference between the investigated
educational background levels in terms of mean TBC levels
during the two follow up visits (visit 2 and 3).

Analysis

of patient attitudes toward the model showed a positive
acceptance.
It is concluded that cholesterol screening in this
community pharmacy was effective, acceptable, and may prove
to be financially feasible if effectively planned.

The

concept of cholesterol testing and follow up should be
tested in other non-academic setting to validate the
findings of this study.

It is expected that younger

individuals (20 years old and above), those at high risk of

119

developing CHD, and patients on medication to lower TBC
will benefit most from such service.
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Appendix A
Consent Form
Cholesterol Screening Project
'icu are baing asked it you vh:h to take part in a cholesterol
screening project. Please read this consent form carefully and ask
as many questions as you like before deciding whether you want to
participate. If you decide to participate in this study, you will
have a finger stick pgrfor;ed hy· a pharmaci$t in order to collect
the necessary blood sample tor the test.
F inqer sticks are
accompanied by minor discomfort at the site of the finger puncture
and may result in slight bruising at the site. Approximately three
drops of blood will be collected.
The time required for this
procedure should be less than five minutes.
If your cholesterol

level is over 200, you will be requested to appear for two followup visits. The screening test we will use may overestimate true
levels.
The benafit yoy gao expect trom this stydy is the knowledge O! your
cholesterol level and whether or not you should racaiva !urther
evaluation by your physician. Elevated blood cholesterol is known
to be directly correlated with a high incidence o! coronary artery
disease which,
i! undatected and untreated,
may lead to
atherosclerosis and heart attack.
The
durotign
gt
your
portieipoting in this study is the time required !or ringer stick,
blood collection and analysis, and answering the awarene•• survey
provided.
At the time of this initial screening, yoy yill be giyen a gopy gt
th• results for your recgrds and a copy will ba torvardad to your
physician, unless.you indicate otherwise. any intgr;otign that is
obtained in connection with this study and that can be identified
with you yi' l rem-ain cgnfidential and will be disclosed only with
your permission.
The sponsor o! this project will receive
sUJDmaries ot the study.
Also, you will be required to complete
forms regarding your health.
I ! you have any questions, please ask. I ! you have any additional
questions later, please contact your pharmacist osama Ibrahim M.s.
at (209) 946-2440, your Campus Pharmacy manager Joel wagner
Pharm·P· at (209) 946-241: or the projee~ coordinator Dr. Patrick
catanio at (209) 946-2491.

Your siqnatur•· indicates that you have read the information
provided and have had your questions answered and have decided to
participate.

I,
, freely give my consent to take part in
this study. I vill receive a copy ot this consent form for future
reference. I have been advised that the Unive~sity o! the Pacific
has no special program by which it provides compensation o! medical
treatment i! injury occurs during biomedical or behavioral
research.

Signature ot Participant

Date

Signature ot Investigator

Date

Your blood cholesterol reading is ______ mg;cll

Date:

I

/1988

Would you like a written screening result to be sent to your
physician or health center?
Yes
No

r

l
'
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Appendix A (Cont.)
Boehringer Mannheim Diagnostic Consent Form

Cholesterol Screening Consent
and Release Statement
I her&by ~ease Boehringer Mannheim Corporarion. othllf orvanizarions associated with this wunmg. parent and affiilattd
companies. successors and assigns. at1d officert dtrectors and employees from any and all liat.t.w ansrng !rom or ri1 any

way connocte<l with blood drawmg for my blood cholestarof measurement or from the data dem!<lthen!lrom. I undmtand
thn
I) The data denved from th~ test are to be considered pl!iiminary on~ and do not constitute ' diagnosis of
irypl!ltholesterolemra.
21 With my permisSion. screening sponso11 may elect to send the results of this test to a Ph!"<~" of my chOICe 11 my
r&SlJI!1 suggest that I may be at mcreased nsk for hean diSease accon!mg to the Nauonal losntutes of Health
guidalmas
31 Boellnnger Mannh•m Corporation will also rece"e a copy of this complet!d form. mcludmg test results. lor resl!illt:h
purp~s on~.

4) The responsibility for initiating a follow-up u:ammauon to confirm high blc:1d cholesterol ar.d cbtarn adv1ce and
ueaunant is mrne and not that of my physictan or the orgamzauons assocrated 'lnth ttns sc::!!nmq.

Date _

Signature

BOEHRINGER
MANN HElM
DIAGNOSTICS

9tt5 Hogut Rood. I - •..... IN 46250
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Appendix B
llJiinora:l.ty of the Pacif.ic;
Sc:bool. of Pbanacy
Cholesterol Sc:rHIIillg Prcjeel:

CRoi.!S'rEROL DATA

SHEET

I

Date:

!I..,.:,T"::="\"'"""~>"t':':=:"l""""-,:zr:rr-1I.ut)
(Firs:)
(Hid)

Telephone 1111111ber: (

Dau of birth:

lleillht:

I I

Sa::

M F

I 1988

)

"

Weisht:

Familr Phrsieian:
Please, m....r the follovillg gueatioas:

l, Do

:rou

-.ka?

!••-

!lo_

l!ov lllllllY eigarottes/day: - - -

2. Ara yon takina Birth Cclltrol Pills?

Yes_

!lo_

~. Ara you & ciiabetie (hish blood sugar)?

Yes_

!lo_ I don't lalov_

-

I

4, What 1a year blood prunn?

I ciou 't lalov

S, What 1a your a:areise l ... el? _Active (at least l/2 hour every day)
_Moderate (at least l/2 h erery other day)
Mild (Weekanda only)
=Mot aetire (lus than onc:a a veelc)
6, Does any person 1o. your family have a history of heart problems, e.g.,
ehest pai.o., hypertoo.sioa, or haart attaelc: Yes_ No_ I cioa 't know_

7. Do yon ha'Ye almormal thyroid ftmc:tioa?
8. What is year Kuc:atiouel left!?

Yes_ No_ I doa't lalov_

_ _ _ Gracia sc:llool
l!igh sthool
Uaciergraduate. studeat
_ _ _ Uadergraduate Degrl!1! (B.A./Phann.D.)
--Postgraduate degree (M.S./ Ph.D.)
-_ _ _ Not suted.

===
9. Are you eurreatly follovillg a

~eeial diet,e.g., lovfat/veight control diet)1

No

y,.,1!

y.;;:- s p e c i f y ' - - - - - - - -

10. Are you talcing preseriptioc 11111<11eatioa on ehronie basis?
No_
Yes
, l!ov """Y'
l
2
3

4

Please, Do not vr1 te below this line

I!W·

Ob:

[g

I R. F.:

··~-

~/dL

Gl!:

N

B

I!

s
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Appendix c
Cholesterol Awareness suryey (Pre-testl

University of the Pacific
School of Pharmacy
Cholesterol Screening Project

Please circle the appropriate answer according to your best knowledse.

1.

Have you ever heard of high blood cholesterol or hyperlipidemia?

Yes

No

2.

Have you ever had your blood cholesterol checked?

Yes

No

3.

Have you been told by a doctor that your blood.cholesterol is high?Yes

No

4.

High blood cholesterol is affected by dietary factors.

5.

Uoes high cholesterol lead to hardening of the blood vessels (arteries)?
Yes No

6.

Uoes high blood cholesterol lead to heart attack ?

7.

Do you think that dietary action such as eating less saturated fats, egg,
and lard would lower blood cholesterol?
Yes No

a.

Uo you believe that reducing elevated blood cholesterol will have a large
effect on heart disease?
Yes No

9.

If you were found to have elevated blood.cholesterol, would you be willing
to make dietary changes and/or

ta~e

True

False

Yes

No

medication to lower your blood level?
___Yes
___No
___I,am not sure

10. Cigarette smoking by itself will increase your risk of heart attack?
____True ____False

t

>----

1
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Appendix D

PATIENT EDUCATION MATERIAL
USED IN THE STUDY

Name of Publication

1. Combat

High Cholesterol

Source

citizens for Public
Action on Cholesterol

2.

Coronary Risk Factors

American Heart Association

3.

Exercise and Your Heart

American Heart Association

4. Your Heart and Dyslipidemia

(It's more than High
cholesterol)

Park-Davis

5. Elevated Cholesterol

Merk Sharp

&

Oehme

Merk Sharp

&

Dohme

6.

Lowering Your ·cholesterol
(Diet information guidelines)

7. Cholesterol, Questran and You

Bristol Laboratories
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Appendix E
Blood Cholesterol Progress Wallet Card

University of the Pacif.ic:
School of Pharmacy

>250

Campus Pharmacy
751 Brookside Road
Stockton, CA 95211

Cholesterol Screening Project

240

(209) 946-2411

Remember.

230

• Know your blood cholesterol level and what it means.
• As a rule of thumb, a 1% reduction i.n blood cholesterol

reduces the incidence of heart attacks by 2%.
• Include lowfat milk/yogurt/cheese, fruits, vegetables,
fish, and only lean meat in your diet
• Avoid lard, butter, egg yolk.. animal organs/skin, ·and
saturated (animal) fat.

~

220

"'E

210
200
190

UOP
school of

pharmacy

Cholesterol
Screening
Project

UOP
school of

phannacy

<180
Test#

1

2

3

4

5

6

Date:

I

I

I

I

I

I

BLOOD CHOLESTEROL PROGRESS CHART

Cholesterol
Screening
Project

\BLOOD CHOLESTEROL PROGRESS CHART
.

··---··-----
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Appendix F
Preliminary Evaluation Sheet

University of the Pacific
School of Pharmacy
Cholesterol Screening Project

If you were found to have a high blood cholesterol level
would you be willing to:
1. Voluntarily modify your diet in an attempt to lower your
elevated cholesterol by eating less saturated fatS and

cholesterol for a one month trial period.

Yes

No

Yes

No

3. Receive appropriate educational material, a pharmacist's
advice,. and answers to your questions on cholesterol.
Yes

No

4.' Be referred to your family physician or a health center
to establish the final diagnosis of your condition.

Yes

No

of your blood lipid profile for follow-up purposes.

Yes

No

6. Receive a certificate of participation in our project.

Yes

No

2. Repeat your blood cholesterol analysis twice by your
pharmacist within a 4 month period (one and three months
after this initial test) absolutely FREE.

5. Give authorization to your pharmacist to receive a copy

Participant's Signature - - - - - - - - - - - - - Date - - - -
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Appendix G
Participant Interest in Future Blood Level Measurements
From the following list, please circle the number
of test(s) which you would use in the future if
they were available in your community pharmacy:

#

Tests

Available

1

Cholesterol

2

Triglycerides

3

Hemoglobin

4

Glucose

5

Uric Acid

6

Serum Creatinine

7

Blood Urea Nitrogen

8

Liver Function Tests
(GGT, SGOT, SGPT)
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Appendix H
Cholesterol Awareness Survey (Post-test)
DaiYera~ty
Sc~ool

of t~e Pac~fic
of ,.ar.acy

Cholesterol Screeaiaa Project

1.
2.

High blood cholesterol is affected by dietary factors.

False

(1 tsp)

(2 oz)

(2 oz)

Which of the following contains the hi1kest amount of saturated fats?
a-2 % milk
(1

4.

Trae

Which of the following contains the hisheat amount of cholesterol?
c-Liver, beef
d-Sea food & fish
b-Butter

a-Egg white
( 1 large)
3.

Pleaae circle tke appropriate aaaver:

cup)

b-Low fat yogurt
( 8 0 z)

c-Coconut oil
(1 tbsp)

d-Shrimp,steamed
(2 oz)

Which of the following contains lov cholesterol content but hiah
1• aaturate4 fat?

a- popcorn (buttered)
5.

b-Apple

c-Coconut oil

d-Skim milk

(2 oz)
{1 cup)
(one)
(1 tbsp)
Does high cholesterol lead to hardening of the blood vessels

(arteries)'?
Yea

lo

Yes

lo

6.

Does high blood cholesterol lead to heart attack ?

7.

Do you think that dietary action such as eating less saturated fats, egg,
and lard would lower blood cholesterol?
Yes
lo

8.

Do you believe that reducing elevated blood cholesterol will have an effect
on heart disease?.
Yes
Jlo

9.

Because of your elevated blood cholesterol, did you make dietary changes
and/or take medication.to lover your blood cholesterol during this study?
Yes

J"o

10. Did you consult with other health care provider (your physician, health
center, or a dietitian to reduce your blood cholesterol as a result of the
screening project~

••

I rl11

Yes: specify - - - - - - - - -

11. What is your attitude toward the idea of screening blood cholesterol in a
community pharmacy done by a pharmacist~
a. I stroaslJ like it

12. Is it a

convenient service for you?

c. I doa't like it
Yes

lo

13. If blood cholesterol analysis were available in your community pharmacy,
would you use this service in the future?
Yes
J"o
14. Would you be willing to pay for this service if it were to be offered in
your neighborhood pharmacy?
•o
Tea: If so, what would be a reasonable fee?
$3 or less
$5
$10
More than SlO
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Appendix I

University of the Pacific
School of Phannacy

CERTIFICATE OF PARTICIPATION
This certifies that

has successfully participated in
The Pharmacist's Cholesterol Screening/Awareness Project
conducted at the School of Pharmacy.
This is a recognition of the participant's effort to lower coronary artery
disease mortality and morbidity and to keep America healthy.
Datedt~--d'J'ol----1988

O......M.1b~,M.S.
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